



National Comprehensive  
Cancer Network®

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

# Systemic Mastocytosis

Version 3.2021 — July 9, 2021

**NCCN.org**

**Continue**



National  
Comprehensive  
Cancer  
Network®

# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

[NCCN Guidelines Index](#)  
[Table of Contents](#)  
[Discussion](#)

**\*Aaron T. Gerds, MD, MS/Chair ‡ † P**  
Case Comprehensive Cancer Center/  
University Hospitals Seidman Cancer Center  
and Cleveland Clinic Taussig Cancer Institute

**\*Jason Gotlib, MD, MS/Vice-Chair ‡**  
Stanford Cancer Institute

**Haris Ali, MD ‡ §**  
City of Hope National Medical Center

**Prithviraj Bose, MD ‡**  
The University of Texas  
MD Anderson Cancer Center

**Mariana Castells, MD, PhD P σ/**  
**Adjunct Panel Member**  
Dana-Farber/Brigham and Women's  
Cancer Center

**Michael W. Deininger, MD, PhD ‡**  
Huntsman Cancer Institute  
at the University of Utah

**Andrew Dunbar, MD †**  
Memorial Sloan Kettering Cancer Center

**Amro Elshoury, MD ‡**  
Roswell Park Comprehensive Cancer Center

**Tracy I. George, MD ≠**  
Huntsman Cancer Institute  
at the University of Utah

**Krishna Gundabolu, MBBS ‡**  
Fred & Pamela Buffett Cancer Center

**Elizabeth Hexner, MD ‡ §**  
Abramson Cancer Center  
at the University of Pennsylvania

**Gabriela S. Hobbs, MD ‡**  
Massachusetts General Hospital  
Cancer Center

**Tania Jain, MBBS †**  
The Sidney Kimmel Comprehensive  
Cancer Center at Johns Hopkins

**Catriona Jamieson, MD, PhD ‡**  
UC San Diego Moores Cancer Center

**Andrew T. Kuykendall, MD ‡ P**  
Moffitt Cancer Center

**Yazan Madanat, MD ‡**  
UT Southwestern Simmons  
Comprehensive Cancer Center

**Brandon McMahon, MD ‡**  
University of Colorado Cancer Center

**Sanjay R. Mohan, MD ‡**  
Vanderbilt-Ingram Cancer Center

**Stephen Oh, MD, PhD ‡**  
Siteman Cancer Center at Barnes-  
Jewish Hospital and Washington  
University School of Medicine

**Animesh Pardanani, MBBS, PhD ‡**  
Mayo Clinic Cancer Center

**Nikolai Podoltsev, MD, PhD ‡**  
Yale Cancer Center/Smilow Cancer Hospital

**Erik Ranheim, MD, PhD ≠**  
University of Wisconsin  
Carbone Cancer Center

**Lindsay Rein, MD ‡**  
Duke Cancer Institute

**Rachel Salit, MD ‡**  
Fred Hutchinson Cancer Research Center/  
Seattle Cancer Care Alliance

**Brady L. Stein, MD, MHS ‡ P**  
Robert H. Lurie Comprehensive Cancer  
Center of Northwestern University

**Moshe Talpaz, MD †**  
University of Michigan Rogel Cancer Center

**Pankit Vachhani, MD ‡**  
O'Neal Comprehensive  
Cancer Center at UAB

**Martha Wadleigh, MD ‡ †**  
Dana-Farber/Brigham and Women's  
Cancer Center

**Katherine Walsh, MD † ‡**  
The Ohio State University Comprehensive  
Cancer Center - James Cancer Hospital  
and Solove Research Institute

**Dawn C. Ward, MD ≠**  
UCLA Jonsson Comprehensive Cancer Center

**NCCN**  
**Mary Anne Bergman**  
**Cindy Hochstetler, PhD**  
**Hema Sundar, PhD**

σ Allergy/Immunology  
‡ Hematology/Hematology oncology  
P Internal medicine  
† Medical oncology  
≠ Pathology  
§ Transplantation  
\* Discussion Writing Committee Member

[NCCN Guidelines Panel Disclosures](#)

**Continue**



### [NCCN Systemic Mastocytosis Panel Members](#) [Summary of Guidelines Updates](#)

- [Diagnostic Algorithm \(SM-1\)](#)
- [Workup \(SM-2\)](#)
- [Treatment for Indolent Systemic Mastocytosis \(ISM\) and Smoldering Systemic Mastocytosis \(SSM\) \(SM-3 and SM-4\)](#)
- [Treatment for Aggressive Systemic Mastocytosis \(ASM\) \(SM-5\)](#)
- [Treatment for Systemic Mastocytosis with an Associated Hematologic Neoplasm \(SM-AHN\) \(SM-6 and SM-7\)](#)
- [Treatment for Mast Cell Leukemia \(SM-8\)](#)
- [2017 World Health Organization \(WHO\) Classification of Mastocytosis \(SM-A\)](#)
- [2017 WHO Diagnostic Criteria for Cutaneous and Systemic Mastocytosis \(SM-B\)](#)
- [2017 Diagnostic Criteria for the Variants of Systemic Mastocytosis \(SM-C\)](#)
- [WHO Criteria for B-Findings and C-Findings \(SM-D\)](#)
- [IWG-MRT-ECNM Criteria for Eligible Organ Damage to Assess Clinical Improvement and Treatment Response \(SM-E\)](#)
- [Recommendations for Histopathology Analysis and KIT D816V Mutation Testing \(SM-G\)](#)
- [Adverse Prognostic Variables and Risk Stratification in Systemic Mastocytosis \(SM-H\)](#)
- [Signs and Symptoms of Mast Cell Activation and Potential Triggers of Mast Cell Activation \(SM-I\)](#)
- [Anti-Mediator Drug Therapy for Mast Cell Activation Symptoms \(SM-J\)](#)
- [Special Considerations for the Management of Patients with Systemic Mastocytosis \(SM-K\)](#)
- [Management of Midostaurin Toxicity \(SM-L\)](#)
- [Management of Avapritinib Toxicity \(SM-M\)](#)

**Clinical Trials:** NCCN believes that the best management for any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, [click here: nccn.org/clinical\\_trials/member\\_institutions.aspx](#).

**NCCN Categories of Evidence and Consensus:** All recommendations are category 2A unless otherwise indicated.

See [NCCN Categories of Evidence and Consensus](#).

**NCCN Categories of Preference:** All recommendations are considered appropriate.

See [NCCN Categories of Preference](#).

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2021.



Updates in Version 3.2021 of the NCCN Guidelines for Systemic Mastocytosis from Version 2.2021 include:

### [SM-5](#)

- *Avapritinib (if platelets  $\geq 50 \times 10^9/L$ ) is a preferred regimen for aggressive systemic mastocytosis (ASM) with the following footnote: *Avapritinib is not recommended for the treatment of patients with advanced SM with platelet counts of less than  $50 \times 10^9/L$ . For the management of avapritinib toxicity, see SM-M.* (Also for SM-7 [SM-AHN], SM-8 [Mast Cell Leukemia]).*

### [SM-K, 2 of 4](#)

- Bullet 6 under Pregnancy, added *avapritinib* to the 2nd sentence.

### [SM-M](#)

- *Management of Avapritinib Toxicity* is a new page.

### [MS-1](#)

- The Discussion has been updated to reflect the changes to the algorithm.

Updates in Version 2.2021 of the NCCN Guidelines for Systemic Mastocytosis from Version 1.2021 include:

### [MS-1](#)

- Discussion section has been updated to reflect the changes in the algorithm.

### [SM-C](#)

- Footnote "a", modified: ASM with  $\geq 5\%$  5%-19% mast cells in bone marrow aspirate is referred to as ASM in transformation (ASM-t).

Updates in Version 1.2021 of the NCCN Guidelines for Systemic Mastocytosis from Version 1.2020 include:

### [SM-1](#)

First column:

- *Biopsy proven* adult-onset MIS.

Second column, 4th bullet, modified to include:

- .. and *KIT D816V is negative*

New column headers added:

▶ Third column: *Diagnostic Criteria*

▶ Fourth column: *Diagnosis*

- Fifth column:  $\pm$  *Hereditary alpha-tryptasemia (HaT)*

Footnotes

- "f", 2<sup>nd</sup> sentence is new: *HaT may be diagnosed alone, but is also enriched in patients with SM, especially indolent or smoldering SM (ISM/SSM). It may also be found with cutaneous mastocytosis. HaT is associated with an increased risk of severe mediator symptoms/anaphylaxis.*

References:

- Greiner G, et al. *Blood* 2021;137:238–247 and Lyons JJ, et al. [J Allergy Clin Immunol](#) 2021;147:622-632 are new to footnote "f."
- Updated: Pardanani A. *Am J Hematol* 2019;94:363-377.

### [SM-2](#)

Sixth bullet, modified:

- *Cytogenetics* is now a sub-bullet under Bone marrow aspirate and biopsy

Eighth bullet, modified:

- *Molecular testing for KIT D816V using an assay with high sensitivity (eg, allele-specific oligonucleotide quantitative reverse transcriptase PCR [ASO-qPCR] or digital droplet PCR). If negative for KIT D816V mutation and*

*eosinophilia is present, then screen for FIP1L1-PDGFR $\alpha$  fusion gene.*

### [SM-5](#)

Third column, Useful in Certain Circumstances, modified:

- *Imatinib only if for KIT D816V mutation negative or unknown; or if Well-differentiated SM (WDSM).*

### [SM-6](#)

Fifth column, upper pathway:

- *Monitor for progression of AHN and SM component*

Fifth column, lower pathway:

- *Monitor for progression of AHN and SM component*

Footnote

- "u" is new to the page: *These algorithms refer to SM-AHN with myeloid neoplasms, which comprise the majority of cases.*

### [SM-A](#)

Footnote

- "c," modified first sentence: *The overwhelming majority (about 90%) of AHNs are myeloid neoplasms...*

### [SM-B](#)

Footnote

- "b" modified to include the following: *Normal mast cell markers include tryptase and CD117. Tryptase is the most specific marker of mast cells. CD117 alone is not sufficient to establish mast cell lineage.*

[Continued](#)

UPDATES



Updates in Version 1.2021 of the NCCN Guidelines for Systemic Mastocytosis from Version 1.2020 include:

### SM-C

- **Significant edits made to Mast cell leukemia.**

#### Footnote

- "a" is new corresponding to Aggressive systemic mastocytosis: **ASM with ≥5% mast cells in bone marrow aspirate is referred to as ASM in transformation (ASM-t).**

### SM-D

#### B-Findings:

- First bullet: deleted and before (focal, dense aggregates)

#### C-Findings:

Third bullet, modified: Skeletal involvement, with large osteolytic lesions (*if the size of the lesion is ≥2 cm, it is considered large*) with or without pathologic fractures (pathologic fractures caused by osteoporosis do not qualify as a C-finding). *Small osteolytic and/or sclerotic lesions do not define advanced SM.* [SM-F \(2 of 2\)](#)

"§" Fifth sentence modified to include **"or mast cell leukemia"**

### SM-G (1 of 3)

- First bullet, modified: Review of the bone marrow or other extracutaneous organ(s) for involvement by neoplastic mast cells should be undertaken by a hematopathologist and/or center with expertise in the *pathology of mast cell diseases. management of patients with mast cell diseases.*
- Third bullet, modified: Bone marrow aspirate and biopsy...  
 ▶ The following footnote is new corresponding to *resembling normal mast cells: Well-differentiated SM is a morphologic variant present in all subtypes of SM.*
- Fourth bullet, modified: Bone marrow core biopsy (1–2 cm)...  
*percent mast cell burden and morphology of mast cells in biopsy (eg, multifocal dense infiltrates [a major diagnostic criterion] or a primarily interstitial pattern of involvement)*
- Sixth bullet, modified: ...which is relatively common in advanced SM>ISM/SSM, particularly in areas of mast cell aggregates.
- Ninth bullet, second sentence, modified: Myeloid mutation panels alone are not recommended for the detection of KIT D816V. Next-generation sequencing (NGS) assays can exhibit low sensitivity and higher-sensitivity assays should always be performed. ~~should be performed on the bone marrow, but can be performed on the peripheral blood in the presence of an AHN and/or circulating mast cells. Myeloid mutation panels are not recommended for the detection of KIT D816V; of approximately 5%.~~

### SM-G (2 of 3)

- First bullet: If a diagnosis...*molecular testing for KIT D816V using an assay with high sensitivity, with the following corresponding footnote: In the absence of a highly sensitive quantitative PCR assay, qualitative PCR can be used.*
- Second bullet, second and third sentences are new: *Fresh bone marrow aspirate is preferable, but formalin-fixed paraffin-embedded tissue can also be used. Decalcified tissue typically interferes with DNA/RNA assays, and thus, decalcified BM should not be used for mutational analysis.* If initial screening of the peripheral blood fails to detect the KIT D816V mutation in a patient with suspected SM, testing of the bone marrow should be undertaken with a highly sensitive assay (eg, ASO-qPCR or digital droplet PCR).
- Fourth bullet, #3, modified: Patients are positive for other mutations at codon 816 (D816H, D816Y, others) or in other regions of KIT that are not detectable by *high-sensitivity assays (eg, ASO-qPCR or digital droplet PCR).*
- Fifth bullet, modified to include: *(eg, ASO-qPCR or digital droplet PCR)*
- Eighth bullet, modified to include: *by high-sensitivity assays (eg, ASO-qPCR or digital droplet PCR)*

### SM-G (3 of 3)

- The following reference is new: Greiner G, Gurbisz M, Ratzinger F, et al. Digital PCR: A sensitive and precise method for KIT D816V quantification in mastocytosis. Clin Chem 2018;64:547-555.


### SM-H (5 of 5)

- Global Prognostic Score Model (GPSM) for predicting PFS and OS in patients with Systemic Mastocytosis are new tables, with the following corresponding reference: Muñoz-González JI, Álvarez-Twose I, Jara-Acevedo M, et al. Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. 2021;8:e194-e204.





### DIAGNOSTIC ALGORITHM FOR THE PATIENT PRESENTING WITH SIGNS OR SYMPTOMS OF MASTOCYTOSIS<sup>a</sup>



<sup>a</sup>The diagnosis of mastocytosis and its subtypes is based on the 2017 WHO Criteria Classification and requires a combination of histopathologic, clinical, laboratory, and cytogenetic/molecular analyses. [See 2017 World Health Organization Classification of Mastocytosis \(SM-A\)](#); [see 2017 WHO Diagnostic Criteria for Cutaneous and Systemic Mastocytosis \(SM-B\)](#); and [see 2017 Diagnostic Criteria for the Variants of Systemic Mastocytosis \(SM-C\)](#).

<sup>b</sup>Patients should be counseled about the signs/symptoms and potential triggers of mast cell activation (See SM-1). Multidisciplinary collaboration with sub-specialists (eg, anesthesia for procedures/surgery; high-risk obstetrics for pregnancy) is recommended (See SM-K).

<sup>c</sup>Serum tryptase level may be <20 ng/mL or only transiently elevated.

<sup>d</sup>See WHO Criteria for B-Findings and C-Findings in Patients with Systemic Mastocytosis (SM-D) and IWG-MRT-ECNM Criteria for Eligible Organ Damage to Assess Clinical Improvement (CI) and Treatment Response (SM-E). B- and C-findings are used for the diagnosis of the WHO subtype of SM (SM-C and SM-D) and IWG-MRT-ECNM criteria are used to establish eligible organ damage findings for clinical trial enrollment and to adjudicate response to therapy (SM-E).

<sup>e</sup>Mast cell markers by flow cytometry immunophenotyping include CD117, CD25, and CD2.

Immunohistochemistry markers include CD117, CD25, and tryptase. For both techniques, CD30 is optional. Also [see SM-2](#).

<sup>f</sup>HαT is a multisystem disorder characterized by duplications and triplications in the *TPSAB1* gene encoding α-tryptase associated with elevation of the basal serum tryptase level and symptoms including cutaneous flushing and pruritus, dysautonomia, functional gastrointestinal symptoms, chronic pain, and connective tissue abnormalities, including joint hypermobility. (Lyons JJ, et al. *Nat Genet* 2016;48:1564-1569). HαT may be diagnosed alone, but is also enriched in patients with SM, especially indolent or smoldering SM (ISM/SSM). It may also be found in patients with cutaneous mastocytosis. HαT is associated with an increased risk of severe mediator symptoms/anaphylaxis. (Greiner G, et al. *Blood* 2021;137:238-247 and Lyons JJ, et al. *J Allergy Clin Immunol* 2021;147:622-632).

<sup>g</sup>Specific criteria have been established for primary and secondary MCAS (Akin C. Mast cell activation syndromes. *J Allergy Clin Immunol* 2017;140:349-355). (See Discussion).

<sup>h</sup>Management of cutaneous mastocytosis is not included in these guidelines. Referral to centers with expertise in cutaneous mastocytosis is strongly recommended.

Adapted from: Pardanani A. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. *Am J Hematol* 2019;94:363-377.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



### WORKUP FOR SUSPECTED SYSTEMIC MASTOCYTOSIS<sup>i</sup>

#### General Diagnostic Studies

- H&P, including prior history of mast cell activation symptoms; history of anaphylaxis; potential triggers; examination for MIS; spleen and liver size by palpation; documentation of medications, transfusion history, and weight loss
- Comprehensive metabolic panel with uric acid, lactate dehydrogenase (LDH), and liver function tests (LFTs)
- Serum tryptase level
- CBC with differential
- Examination of blood smear (eg, monocytosis, eosinophilia, dysplasia)<sup>j</sup>
- Bone marrow aspirate and biopsy with<sup>l</sup>:
  - ▶ Flow cytometry: CD34, CD117, CD25, CD2; CD30 (optional)
  - ▶ Immunohistochemistry: CD117, CD25, tryptase; CD30 (optional)
  - ▶ Cytogenetics
- FISH as needed for associated hematologic neoplasm (AHN)-related abnormalities<sup>j</sup>
- Molecular testing for *KIT* D816V using an assay with high sensitivity (eg, allele-specific oligonucleotide quantitative reverse transcriptase PCR [ASO-qPCR] or digital droplet PCR).<sup>j,k,l</sup> If negative for *KIT* D816V mutation and eosinophilia is present, then screen for *FIP1L1-PDGFR* fusion gene.
- Myeloid mutation panel (eg, containing *SRSF2*, *ASXL1*, *RUNX1*)<sup>j,k,l</sup>

#### Evaluation of B- and C-Findings and Organ Involvement<sup>d</sup>

- CT/MRI or ultrasound of the abdomen/pelvis
- DEXA scan to evaluate for osteopenia/osteoporosis
- Metastatic skeletal survey to evaluate for osteolytic lesions
- Organ-directed biopsy (eg, endoscopy, liver biopsy) as needed with immunohistochemistry (CD117, CD25, tryptase, and CD3 as a control T-cell marker)

#### Useful Under Selected Circumstances

- 24-hour urine studies for biochemical evidence of mast cell activation
  - ▶ N-methylhistamine
  - ▶ Prostaglandin D2
  - ▶ 2,3-Dinor-11beta-prostaglandin F2 alpha
- HLA testing, if considering allogeneic hematopoietic cell transplant (HCT)
- Assessment of symptom burden and quality of life (QOL) using the Mastocytosis Symptom Assessment form (MSAF) and the Mastocytosis Quality of Life Questionnaire (MQLQ)<sup>m</sup>

<sup>d</sup>See [WHO Criteria for B-Findings and C-Findings in Patients with Systemic Mastocytosis \(SM-D\)](#) and [IWG-MRT-ECNM Criteria for Eligible Organ Damage to Assess Clinical Improvement \(CI\) and Treatment Response \(SM-E\)](#). B- and C-findings are used for the diagnosis of the WHO subtype of SM ([SM-C](#) and [SM-D](#)) and IWG-MRT-ECNM criteria are used to establish eligible organ damage findings for clinical trial enrollment and to adjudicate response to therapy ([SM-E](#)).

<sup>j</sup>See [2017 Diagnostic Criteria for the Variants of Systemic Mastocytosis \(SM-C\)](#).

<sup>l</sup>See [Recommendations for Histopathology Analysis and \*KIT\* D816V Mutation Testing in Systemic Mastocytosis \(SM-G 1 of 3\) and \(SM-G 2 of 3\)](#).

<sup>k</sup>Preferred on the bone marrow, as yield from the peripheral blood may be lower; exceptions may be patients with SM-AHN or MCL. See [SM-G 2 of 3](#).

<sup>l</sup>See [Adverse Prognostic Variables and Risk Stratification in Systemic Mastocytosis \(SM-H\)](#).

<sup>m</sup>van Anrooij D, et al. *Allergy* 2016;71:1585-1593. MSAF and MQLQ have been validated only in patients with ISM, not in patients with more advanced forms of mast cell disease. To access the questionnaires for MSAF and MQLQ, select "Supporting Information" and "See Appendix S1 and Appendix S2."

### CLASSIFICATION<sup>i</sup>

Indolent SM (ISM)  
([SM-3](#)) and ([SM-4](#))

Smoldering SM (SSM)  
([SM-3](#)) and ([SM-4](#))

Aggressive SM (ASM) ([SM-5](#))

SM with an associated  
hematologic neoplasm  
(SM-AHN) ([SM-6](#)) and ([SM-7](#))

Mast cell leukemia  
(MCL) ([SM-8](#))

**Note:** All recommendations are category 2A unless otherwise indicated.


**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

### TREATMENT FOR INDOLENT SYSTEMIC MASTOCYTOSIS (ISM) AND SMOLDERING SYSTEMIC MASTOCYTOSIS (SSM)<sup>i</sup>



<sup>b</sup>Patients should be counseled about the signs/symptoms and potential triggers of mast cell activation ([See SM-I](#)). Multidisciplinary collaboration with sub-specialists (eg, anesthesia for procedures/surgery; high-risk obstetrics for pregnancy) is recommended ([See SM-K](#)).

<sup>d</sup>[See WHO Criteria for B-Findings and C-Findings in Patients with Systemic Mastocytosis \(SM-D\)](#) and [IWG-MRT-ECNM Criteria for Eligible Organ Damage to Assess Clinical Improvement \(CI\) and Treatment Response \(SM-E\)](#). B- and C-findings are used for the diagnosis of the WHO subtype of SM ([SM-C](#) and [SM-D](#)) and IWG-MRT-ECNM criteria are used to establish eligible organ damage findings for clinical trial enrollment and to adjudicate response to therapy ([SM-E](#)).

<sup>i</sup>[See 2017 Diagnostic Criteria for the Variants of Systemic Mastocytosis \(SM-C\)](#).

<sup>j</sup>[See Adverse Prognostic Variables and Risk Stratification in Systemic Mastocytosis \(SM-H\)](#).

<sup>m</sup>van Anrooij D, et al. Allergy 2016;71:1585-1593. MSAF and MQLQ have been validated only in patients with ISM, not in patients with more advanced forms of mast cell disease. [To access the questionnaires for MSAF and MQLQ](#), select "Supporting Information" and "See Appendix S1 and Appendix S2."


**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.





### TREATMENT FOR INDOLENT SYSTEMIC MASTOCYTOSIS (ISM) AND SMOLDERING SYSTEMIC MASTOCYTOSIS (SSM)<sup>l</sup>



<sup>b</sup>Patients should be counseled about the signs/symptoms and potential triggers of mast cell activation ([See SM-I](#)). Multidisciplinary collaboration with sub-specialists (eg, anesthesia for procedures/surgery; high-risk obstetrics for pregnancy) is recommended ([See SM-K](#)).

<sup>i</sup>[See 2017 Diagnostic Criteria for the Variants of Systemic Mastocytosis \(SM-C\)](#).

<sup>l</sup>[See Adverse Prognostic Variables and Risk Stratification in Systemic Mastocytosis \(SM-H\)](#).

<sup>m</sup>van Anrooij D, et al. Allergy 2016;71:1585-1593. MSAF and MQLQ have been validated only in patients with ISM, not in patients with more advanced forms of mast cell disease. [To access the questionnaires for MSAF and MQLQ](#), select "Supporting Information" and "See Appendix S1 and Appendix S2."

<sup>n</sup>[See \(SM-J\)](#) for anti-mediator drug therapy approaches for mast cell activation symptoms.

<sup>o</sup>Cladribine and peginterferon alfa-2a are generally recommended only for patients with advanced SM. However, these agents may also be useful in selected patients with ISM or SSM with severe, refractory mediator symptoms or bone disease not responsive to anti-mediator therapy or bisphosphonates.

<sup>p</sup>Response assessment should be based on improvement of disease-related symptoms and/or improvement of B-findings in ISM or SSM.


<sup>q</sup>Bone marrow aspirate and biopsy, serum tryptase level, and additional staging studies should be performed as clinically indicated (if supported by increased symptoms and signs of progression). [See Discussion](#).

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



### TREATMENT FOR AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM)<sup>1</sup>



<sup>b</sup>Patients should be counseled about the signs/symptoms and potential triggers of mast cell activation ([See SM-I](#)). Multidisciplinary collaboration with sub-specialists (eg, anesthesia for procedures/surgery; high-risk obstetrics for pregnancy) is recommended ([SM-K](#)).

<sup>d</sup>[See WHO Criteria for B-Findings and C-Findings in Patients with Systemic Mastocytosis \(SM-D\)](#) and [IWG-MRT-ECNM Criteria for Eligible Organ Damage to Assess Clinical Improvement \(CI\) and Treatment Response \(SM-E\)](#). B- and C-findings are used for the diagnosis of the WHO subtype of SM ([SM-C](#) and [SM-D](#)) and IWG-MRT-ECNM criteria are used to establish eligible organ damage findings for clinical trial enrollment and to adjudicate response to therapy ([SM-E](#)).

<sup>i</sup>[See 2017 Diagnostic Criteria for the Variants of Systemic Mastocytosis \(SM-C\)](#).

<sup>1</sup>[See Adverse Prognostic Variables and Risk Stratification in Systemic Mastocytosis \(SM-H\)](#).

<sup>n</sup>[See \(SM-J\)](#) for anti-mediator drug therapy approaches for mast cell activation

symptoms.

<sup>q</sup>Bone marrow aspirate and biopsy, serum tryptase level, and additional staging studies should be performed as clinically indicated (if supported by increased symptoms and signs of progression). [See Discussion](#).

<sup>r</sup>Avapritinib is not recommended for the treatment of patients with advanced SM with platelet counts of less than  $50 \times 10^9/L$ . For the management of avapritinib toxicity, [see SM-M](#).

<sup>s</sup>For management of midostaurin toxicity, [see SM-L](#).

<sup>t</sup>For patients with advanced SM, cladribine may be particularly useful when rapid debulking of disease is required whereas peginterferon alfa-2a, which has a cytostatic mechanism of action, may be more suitable for patients with slowly progressive disease without the need for rapid cytoreduction.

<sup>u</sup>[See 2013 IWG-MRT-ECNM Consensus Response Criteria \(SM-F\)](#). Clinical benefit may not reach the threshold of the 2013 IWG-MRT-ECNM response criteria.

**Note:** All recommendations are category 2A unless otherwise indicated.


**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

### TREATMENT FOR SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGIC NEOPLASM (SM-AHN)<sup>i</sup>



<sup>b</sup>Patients should be counseled about the signs/symptoms and potential triggers of mast cell activation ([See SM-I](#)). Multidisciplinary collaboration with sub-specialists (eg, anesthesia for procedures/surgery; high-risk obstetrics for pregnancy) is recommended ([See SM-K](#)).

<sup>i</sup>[See 2017 Diagnostic Criteria for the Variants of Systemic Mastocytosis \(SM-C\)](#).

<sup>j</sup>[See Adverse Prognostic Variables and Risk Stratification in Systemic Mastocytosis \(SM-H\)](#).

<sup>n</sup>[See \(SM-J\)](#) for anti-mediator drug therapy approaches for mast cell activation symptoms.

<sup>v</sup>These algorithms refer to SM-AHN with myeloid neoplasms, which comprise the majority of cases.

**Note:** All recommendations are category 2A unless otherwise indicated.


**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

### TREATMENT FOR SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGIC NEOPLASM (SM-AHN)<sup>i</sup>



<sup>i</sup>See 2017 Diagnostic Criteria for the Variants of Systemic Mastocytosis (SM-C).

<sup>j</sup>See Adverse Prognostic Variables and Risk Stratification in Systemic Mastocytosis (SM-H).

<sup>q</sup>Bone marrow aspirate and biopsy, serum tryptase level, and additional staging studies should be performed as clinically indicated (if supported by increased symptoms and signs of progression). [See Discussion](#).

<sup>r</sup>Avapritinib is not recommended for the treatment of patients with advanced SM with platelet counts of less than 50 X 10<sup>9</sup>/L. For the management of avapritinib

toxicity, [see SM-M](#).

<sup>s</sup>For management of midostaurin toxicity, [see SM-L](#).

<sup>t</sup>For patients with advanced SM, cladribine may be particularly useful when rapid debulking of disease is required whereas peginterferon alfa-2a, which has a cytostatic mechanism of action, may be more suitable for patients with slowly progressive disease without the need for rapid cytoreduction.

<sup>u</sup>[See 2013 IWG-MRT-ECNM Consensus Response Criteria \(SM-F\)](#). Clinical benefit may not reach the threshold of the 2013 IWG-MRT-ECNM response criteria.

**Note:** All recommendations are category 2A unless otherwise indicated.


**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

### TREATMENT FOR MAST CELL LEUKEMIA<sup>l,w</sup>



<sup>b</sup>Patients should be counseled about the signs/symptoms and potential triggers of mast cell activation (See SM-I). Multidisciplinary collaboration with sub-specialists (eg, anesthesia for procedures/surgery; high-risk obstetrics for pregnancy) is recommended (See SM-K).

<sup>i</sup>See 2017 Diagnostic Criteria for the Variants of Systemic Mastocytosis (SM-C).

<sup>l</sup>See Adverse Prognostic Variables and Risk Stratification in Systemic Mastocytosis (SM-H).

<sup>n</sup>See (SM-J) for anti-mediator drug therapy approaches for mast cell activation symptoms.

<sup>q</sup>Bone marrow aspirate and biopsy, serum tryptase level, and additional staging

studies should be performed as clinically indicated (if supported by increased symptoms and signs of progression). See Discussion.

<sup>r</sup>Avapritinib is not recommended for the treatment of patients with advanced SM with platelet counts of less than 50 X 10<sup>9</sup>/L. For the management of avapritinib toxicity, see SM-M.

<sup>s</sup>For management of midostaurin toxicity, see SM-L.

<sup>u</sup>See 2013 IWG-MRT-ECNM Consensus Response Criteria (SM-F). Clinical benefit may not reach the threshold of the 2013 IWG-MRT-ECNM response criteria.

<sup>w</sup>Patients with chronic MCL have no organ damage. However, treatment should be considered given the poor prognosis of MCL.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.





### 2017 WORLD HEALTH ORGANIZATION (WHO) CLASSIFICATION OF MASTOCYTOSIS<sup>1</sup>

1. Cutaneous mastocytosis (CM)
2. Systemic mastocytosis (SM)
  - a. Indolent systemic mastocytosis (ISM)<sup>a</sup>
  - b. Smoldering systemic mastocytosis (SSM)<sup>a</sup>
  - c. Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN)<sup>b,c</sup>
  - d. Aggressive systemic mastocytosis (ASM)<sup>a</sup>
  - e. Mast cell leukemia (MCL)
3. Mast cell sarcoma (MCS)

#### Footnotes

<sup>a</sup>These subtypes require information regarding B- and C-findings for complete diagnosis, all of which may not be available at the time of initial tissue diagnosis. [See WHO Criteria for B-Findings and C-Findings in Patients with Systemic Mastocytosis \(SM-D\).](#)

<sup>b</sup>This category is equivalent to the previously described “systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease (SM-AHNMD).” AHNMD and AHN can be used synonymously.

<sup>c</sup>The overwhelming majority (about 90%) of AHNs are myeloid neoplasms (eg, MDS, MPN, MDS/MPN (eg, chronic myelomonocytic leukemia), chronic eosinophilic leukemia (CEL), or acute myeloid leukemia (AML). Uncommonly, lymphoid neoplasms may occur with SM (eg, chronic lymphocytic leukemia, multiple myeloma, non-hodgkin lymphomas).

#### References

<sup>1</sup>Adapted with permission from Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition. IARC, Lyon, 2017.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

**2017 WHO DIAGNOSTIC CRITERIA FOR CUTANEOUS AND SYSTEMIC MASTOCYTOSIS<sup>1</sup>****CUTANEOUS MASTOCYTOSIS (CM)**

Skin lesions demonstrating the typical findings of urticaria pigmentosa (UP)/maculopapular cutaneous mastocytosis (MPCM), diffuse cutaneous mastocytosis or solitary mastocytoma, and typical histologic infiltrates of mast cells in a multifocal or diffuse pattern in an adequate skin biopsy.<sup>a</sup> In addition, a diagnostic prerequisite for the diagnosis of CM is the absence of features/criteria sufficient to establish the diagnosis of SM.

**SYSTEMIC MASTOCYTOSIS (SM)**

The diagnosis of SM can be made when the major criterion and at least one minor criterion are present, or when three or more minor criteria are present.

**Major criterion:**

**Multifocal, dense infiltrates of mast cells (≥15 mast cells in aggregates) detected in sections of bone marrow and/or other extracutaneous organ(s).**

**Minor criteria:**

1. In biopsy sections of bone marrow or other extracutaneous organs, >25% of the mast cells in the infiltrate are spindle-shaped or have atypical morphology or >25%, of all mast cells in bone marrow aspirate smears, are immature or atypical.
2. Detection of an activating point mutation at codon 816 of *KIT* in the bone marrow, blood, or another extracutaneous organ.
3. Mast cells in bone marrow, blood, or other extracutaneous organs express CD25, with or without CD2, in addition to normal mast cell markers.<sup>b</sup>
4. Serum total tryptase persistently >20 ng/mL (unless there is an associated myeloid neoplasm, in which case this parameter is not valid).

**Footnotes**

<sup>a</sup>This criterion applies to both the dense focal and the diffuse mast cell infiltrates in the biopsy.

<sup>b</sup>CD25 is the more sensitive marker, by both flow cytometry and immunohistochemistry. Normal mast cell markers include tryptase and CD117. Tryptase is the most specific marker of mast cells. CD117 alone is not sufficient to establish mast cell lineage.

**References**

<sup>1</sup>Adapted with permission from Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition. IARC, Lyon, 2017.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

**2017 DIAGNOSTIC CRITERIA FOR THE VARIANTS OF SYSTEMIC MASTOCYTOSIS<sup>1</sup>****Indolent systemic mastocytosis**

- Meets the general criteria for systemic mastocytosis
- No C-findings<sup>a</sup>
- No evidence of an associated hematologic neoplasm
- Low mast cell burden
- Skin lesions are frequently present

**Bone marrow mastocytosis**

- As above (indolent systemic mastocytosis), but with bone marrow involvement and no skin lesions

**Smoldering systemic mastocytosis**

- Meets the general criteria for systemic mastocytosis
- ≥2 B-findings; no C-findings<sup>a</sup>
- No evidence of an associated hematologic neoplasm
- High mast cell burden
- Does not meet the criteria for mast cell leukemia

**Systemic mastocytosis with an associated hematologic neoplasm**

- Meets the general criteria for systemic mastocytosis
- Meets the criteria for an associated hematologic neoplasm (ie, a myelodysplastic syndrome, myeloproliferative neoplasm, acute myeloid leukemia, lymphoma or another hematologic neoplasm classified as a distinct entity in the WHO classification)

**Aggressive systemic mastocytosis (ASM)<sup>a</sup>**

- Meets the general criteria for systemic mastocytosis
- ≥1 C-finding<sup>b</sup>
- Does not meet the criteria for mast cell leukemia
- Skin lesions are usually absent

**Mast cell leukemia (MCL)**

- Bone marrow aspirate smears show ≥20% mast cells
- In classic cases, mast cells account for ≥10% of the peripheral blood white blood cells, but the aleukemic variant (in which mast cells account for <10%) is more common
- Mast cell variants include:
  - Acute MCL [≥1 C-finding(s)] vs. chronic MCL (no C-findings)
  - MCL with an AHN vs. MCL without an AHN
  - Primary (de novo) vs. secondary MCL (arising from another SM variant)
- Skin lesions are usually absent

<sup>1</sup>Adapted with permission from Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition. IARC, Lyon, 2017.

**Footnotes**

<sup>a</sup>ASM with 5%-19% mast cells in bone marrow aspirate is referred to as ASM in transformation (ASM-t).

<sup>b</sup>B- and C-findings indicate organ involvement without and with organ dysfunction, respectively. [See WHO Criteria for B-Findings and C-Findings in Patients with Systemic Mastocytosis \(SM-D\).](#)

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



### WORLD HEALTH ORGANIZATION (WHO) CRITERIA FOR B-FINDINGS AND C-FINDINGS IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS (SM)<sup>a,1</sup>

**B-Findings:** Indicate a high burden of mast cells (MCs) and expansion of the neoplastic process into multiple hematopoietic lineages, without evidence of organ damage

- High mast cell burden (shown on bone marrow biopsy): >30% infiltration of cellularity by mast cells (focal, dense aggregates) AND serum total tryptase >200 ng/mL.
- Signs of dysplasia or myeloproliferation in non-mast cell lineage(s), but criteria are not met for definitive diagnosis of an associated hematologic neoplasm, with normal or only slightly abnormal blood counts.
- Hepatomegaly without impairment of liver function, palpable splenomegaly without hypersplenism, and/or lymphadenopathy on palpation or imaging.

**C-Findings:** Are indicative of organ damage produced by MC infiltration (should be confirmed by biopsy if possible)

- Bone marrow dysfunction caused by neoplastic mast cell infiltration, manifested by  $\geq 1$  cytopenia; absolute neutrophil count  $< 1.0 \times 10^9/L$ , hemoglobin level  $< 10$  g/dL, and/or platelet count  $< 100 \times 10^9/L$
- Palpable hepatomegaly with impairment of liver function, ascites, and/or portal hypertension
- Skeletal involvement, with large osteolytic lesions (if the size of the lesion is  $\geq 2$  cm, it is considered large) with or without pathologic fractures (pathologic fractures caused by osteoporosis do not qualify as a C-finding). Small osteolytic and/or sclerotic lesions do not define advanced SM.
- Palpable splenomegaly with hypersplenism
- Malabsorption with weight loss due to gastrointestinal mast cell infiltrates

#### Footnotes

<sup>a</sup>In patients with SM in whom less than 2 B-findings and no C-findings are detected (category A), the diagnosis is indolent SM (ISM). When 2 or more B-findings but no C-findings are present, the diagnosis is smoldering SM (SSM). When 1 or more C-findings (with or without additional B-findings) are detected, the final diagnosis is either ASM (<20% MCs in BM smears) or MC leukemia (MCs  $\geq 20\%$  on BM smears).

#### References

<sup>1</sup>Adapted with permission from Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition. IARC, Lyon, 2017.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

### IWG-MRT-ECNM CRITERIA FOR ELIGIBLE ORGAN DAMAGE TO ASSESS CLINICAL IMPROVEMENT (CI) AND TREATMENT RESPONSE<sup>1</sup>

#### Nonhematologic

Organ Damage	Organ Damage Eligible for CI Response	CI Response Criteria
Ascites or pleural effusions	(1) Symptomatic ascites or pleural effusion requiring medical intervention such as use of diuretics (grade 2), OR (2) ≥2 therapeutic paracenteses or thoracenteses at least 28 d apart over 12 wk prior to study entry (grade 3), and one of the procedures is performed during the 6 wk prior to drug start	(1) Complete resolution of symptomatic ascites or pleural effusion* AND no longer in need of diuretic(s) for ≥12 wk, OR (2) No therapeutic paracentesis or thoracentesis for ≥12 wk
Liver function abnormalities	≥ Grade 2 abnormalities in direct bilirubin, AST, ALT, or AP <sup>†</sup> in the presence of ascites, and/or clinically-relevant portal hypertension, and/or liver MC infiltration that is biopsy-proven or other causes for abnormal liver function are not identified	Reversion of 1 or more liver function tests to normal range for ≥12 wk
Hypoalbuminemia	≥ Grade 2 hypoalbuminemia (<3.0 g/dL)	Reversion of albumin to normal range for ≥12 wk
Symptomatic marked splenomegaly	Symptomatic marked splenomegaly: a spleen that is palpable >5 cm below the left costal margin and the patient endorses symptoms of discomfort and/or early satiety	≥50% reduction in palpable splenomegaly and no endorsement of discomfort and/or early satiety for ≥12 wk (3D computed tomography/magnetic resonance imaging evaluation may also be undertaken.)

The response criteria were determined using National Institutes of Health CTC version 4.03.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; AP, alkaline phosphatase; PRBC, packed red blood cells

\*Radiologic use of the term trace or minimal for ascites or pleural effusion indicates a substantial improvement of pretreatment pathologic fluid accumulation, which required medical intervention. These terms are acceptable in the absence of the radiologists' use of the term(s) complete disappearance or resolution to describe the change in ascites or effusion.

†Gamma-glutamyl transferase can be used to determine the liver vs bone origin of alkaline phosphatase but is not considered eligible as a liver-related organ damage laboratory abnormality. The grades and associated laboratory ranges above the upper limit of normal used for the total bilirubin according to CTC version 4.03 should be applied to the direct bilirubin.

<sup>1</sup>Gotlib J, Pardanani A, Akin C, et al. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood 2013;121(13):2393-2401.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

SM-E  
1 OF 2





# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

### IWG-MRT-ECNM CRITERIA FOR ELIGIBLE ORGAN DAMAGE TO ASSESS CLINICAL IMPROVEMENT (CI) AND TREATMENT RESPONSE<sup>1</sup>

#### Hematologic

Organ Damage	Organ Damage Eligible for CI Response	CI Response Criteria
<b>ANC</b>	<b>Baseline grade <math>\geq 3</math> ANC (<math>&lt;1 \times 10^9/L</math>)</b>	<b>A minimum 100% increase in the ANC and an ANC of at least <math>0.5 \times 10^9/L</math> for <math>\geq 12</math> wk</b>
<b>Anemia (transfusion-independent)</b>	<b>Grade <math>\geq 2</math> anemia (Hb <math>&lt;10</math> g/dL)</b>	<b>An increase in Hb level of at least 2 g/dL that is maintained for <math>\geq 12</math> wk</b>
<b>Anemia (transfusion-dependent)</b>	<b>Transfusion of a minimum of 6 units of PRBC in the 12 wk before the start of treatment with the most recent transfusion occurring in the previous 4 wk. RBC transfusions are only considered as part of the baseline criteria if they are administered for an Hb level <math>\leq 8.5</math> g/dL and not associated with bleeding, hemolysis, or therapy</b>	<b>Transfusion independence for <math>\geq 12</math> wk and maintenance of a minimal Hb level of 8.5 g/dL at the end of the 12 wk period of response duration</b>
<b>Thrombocytopenia (transfusion-independent)</b>	<b>Grade <math>\geq 2</math> thrombocytopenia (<math>&lt;75 \times 10^9/L</math>)</b>	<b>A minimum 100% increase in the platelet count and an absolute platelet count increase of at least <math>50 \times 10^9/L</math> and no need for platelet transfusions for <math>\geq 12</math> wk</b>
<b>Thrombocytopenia (transfusion-dependent)</b>	<b>1) Transfusion of a minimum of 6 units of apheresed platelets during the 12 wk preceding treatment; and 2) at least 2 units transfused in the previous 4 wk; and 3) transfusions are administered only for a platelet count <math>&lt;20 \times 10^9/L</math></b>	<b>Transfusion-independence for a minimal period of 12 wk and maintenance of a platelet count of <math>\geq 20 \times 10^9/L</math></b>

<sup>1</sup>Gotlib J, Pardanani A, Akin C, et al. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood 2013;121(13):2393-2401.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



### IWG-MRT-ECNM CONSENSUS RESPONSE CRITERIA FOR PATIENTS WITH ASM, MCL, AND SM ASSOCIATED WITH A MYELOID NEOPLASM<sup>1</sup>

#### Complete remission (CR)\*

Requires all 4 criteria and response duration must be ≥12 wk

No presence of compact neoplastic mast cell aggregates in the BM or other biopsied extracutaneous organ

Serum tryptase level <20 ng/mL<sup>†</sup>

Peripheral blood count remission defined as ANC ≥1 x 10<sup>9</sup>/L with normal differential, Hb level ≥11 g/dL, and platelet count ≥100 x 10<sup>9</sup>/L

Complete resolution of palpable hepatosplenomegaly and all biopsy-proven or suspected SM-related organ damage (CI findings)<sup>‡</sup>

#### Partial remission (PR)\*

Requires all 3 criteria and response duration must be ≥12 wk, in the absence of both CR and progressive disease (PD)

Reduction by ≥50% in neoplastic MCs in the marrow and/or or other extracutaneous organ at biopsy demonstrating eligible SM-related organ damage

Reduction of serum tryptase level by ≥50%<sup>†</sup>

Resolution of 1 or more biopsy-proven or suspected SM-related organ damage (CI finding(s))<sup>‡</sup>

#### Clinical improvement (CI)\*

Response duration must be ≥12 wk

Requires 1 or more of the nonhematologic and/or hematologic response criteria to be fulfilled (see Table 3) in the absence of both CR/PR assignment or progressive disease (PD)

#### Stable disease (SD)

Not meeting criteria for CR, PR, CI, or PD ([Continued](#))

Guidelines for adjudicating response are as follows: (1) Only disease-related ≥ grade 2 organ damage is evaluable as a primary endpoint in clinical trials. (2) Response adjudications of CR, PR, SD, PD, and LOR should only be applied to these ≥ grade 2 organ damage findings in the context of trials. (3) Disease status at the time of patient removal from the study singularly relates to the updated status of initial ≥ grade 2 organ damage finding(s). (4) Exclusion of drug-related toxicity and/or other clinical issues (eg, gastrointestinal tract bleeding in the case of worsening anemia/transfusion-dependence) should be undertaken before assigning the designation PD or LOR in a patient with worsening of baseline ≥ grade 2 organ damage.

\*Responses that are not maintained or confirmed for a period of at least 12 wk do not fulfill criteria for CR, PR, or CI; however, both maintained and unmaintained (<12-wk duration) responses in organ damage should be recorded to determine median duration of response.

<sup>†</sup>Only valid as a response criterion if the pretreatment serum tryptase level is ≥ 40 ng/mL.

<sup>‡</sup>Biopsy of organ(s) in addition to the BM to evaluate for SM-related organ damage may be considered.

<sup>1</sup>Gotlib J, Pardanani A, Akin C, et al. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood 2013;121(13):2393-2401.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



### IWG-MRT-ECNM CONSENSUS RESPONSE CRITERIA FOR PATIENTS WITH ASM, MCL, AND SM ASSOCIATED WITH A MYELOID NEOPLASM<sup>1</sup>

#### **Progressive disease (PD)**<sup>§</sup>

Requires at least 1 element of either criteria 1 or 2 and duration must be ≥8 weeks

(1) For patients with baseline grade 2 nonhematologic organ damage:

a) worsening by 1 grade, AND

b) minimum 100% increase (doubling) of laboratory abnormality

For patients with baseline ≥ grade 2 albumin:

(a) worsening by 1 grade, AND

(b) decrease by ≥0.5 g/dL

For patients with baseline ≥ grade 3 nonhematologic organ damage: minimum 100% increase (doubling) of laboratory abnormality

For patients with baseline ≥ grade 2 transfusion-independent anemia or thrombocytopenia: New transfusion dependence of ≥ 4 units of RBCs or platelets at 8 weeks

For patients with baseline transfusion-dependent anemia or thrombocytopenia: ≥100% increase in the average transfusion frequency for an 8-week period compared with the 12-week pretreatment period

For patients with baseline grade ≥ grade 3 neutropenia:

(a) >50% decrease in neutrophil count, AND

(b) absolute decrease of neutrophil count of ≥250/mm<sup>3</sup>, AND

(c) grade 4

(2) Development of at least 10-cm palpable symptomatic splenomegaly for a baseline spleen size of not palpable or ≤5 cm, OR if baseline symptomatic splenomegaly is >5 cm, a >50% worsening and development of at least 10 cm of palpable symptomatic splenomegaly compared with the baseline value.<sup>¶</sup>

#### **Loss of response (LOR)**

Loss of a documented CR, PR, or CI that must be for ≥8 week. Downgrading of CR to PR or PR to CI is considered as such but is not considered as loss of response unless CI is also lost for a minimum of 8 week. The baseline value for LOR is the pretreatment measurement(s) and not the nadir values during response.

Guidelines for adjudicating response are as follows: (1) Only disease-related ≥ grade 2 organ damage is evaluable as a primary endpoint in clinical trials. (2) Response adjudications of CR, PR, SD, PD, and LOR should only be applied to these ≥ grade 2 organ damage findings in the context of trials. (3) Disease status at the time of patient removal from the study singularly relates to the updated status of initial ≥ grade 2 organ damage finding(s). (4) Exclusion of drug-related toxicity and/or other clinical issues (eg, gastrointestinal tract bleeding in the case of worsening anemia/transfusion-dependence) should be undertaken before assigning the designation PD or LOR in a patient with worsening of baseline ≥ grade 2 organ damage.

<sup>§</sup>Preservation of at least one CI finding permits a patient to maintain the response of 'CI' if 1 or more CI findings are lost but none meet criteria for progressive disease (PD). However, if 1 or more of the CI findings become PD, then the CI finding assignment is lost and the patient meets criteria for PD. The baseline value for evaluating PD is the pretreatment measurement(s). The PD findings must be considered related to the underlying disease and not to other clinical factors. Progression of an underlying chronic myeloid neoplasm to AML or mast cell leukemia is also considered PD in the setting of clinical trials.

<sup>¶</sup>For clinical trials using 3D computed tomography or magnetic resonance imaging as an additional modality to quantify organomegaly, progression in splenomegaly is defined as an increase in spleen volume of at least 25%.

<sup>1</sup>Gotlib J, Pardanani A, Akin C, et al. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood 2013;121(13):2393-2401.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**RECOMMENDATIONS FOR HISTOPATHOLOGY ANALYSIS AND *KIT* D816V MUTATION TESTING****HISTOPATHOLOGY ANALYSIS**

- Review of the bone marrow or other extracutaneous organ(s) for involvement by neoplastic mast cells should be undertaken by a hematopathologist and/or center with expertise in the pathology of mast cell diseases.
- The peripheral blood smear should be reviewed for the presence of mast cells (eg, mast cell leukemia) and/or for evidence of an AHN (eg, dysplasia, monocytosis, and/or eosinophilia). The percentage of circulating mast cells should be reported in patients with mast cell leukemia (eg,  $\geq 10\%$  vs.  $< 10\%$  mast cells [aleukemic variant]).
- Bone marrow aspirate and biopsy should include comment on the percentage of neoplastic mast cells, and their morphology (spindle-shaped, well-differentiated [resembling normal mast cells],<sup>a</sup> and immature [eg, promastocytes with indented or bilobed nuclei or metachromatic blasts]). The percentage of abnormal mast cells out of total mast cells should be determined. The aspirate should also be reviewed for features of an AHN.
- Bone marrow core biopsy (1–2 cm) analysis should include comment on the percent mast cell burden and morphology of mast cells in biopsy (eg, multifocal dense infiltrates [a major diagnostic criterion] or a primarily interstitial pattern of involvement). In cases with a primarily interstitial pattern of mast cells, peripheral blood eosinophilia, and negativity for *KIT* D816V mutation, then the *FIP1L1-PDGFR*A fusion gene should be tested.
- On the core biopsy, immunohistochemistry with markers for mast cell tryptase, CD117, and CD25 should be performed to optimize quantification of the bone marrow biopsy mast cell burden. Cytoplasmic and/or surface expression of CD30 may be found on mast cells, especially in advanced disease, but is considered an optional immunohistochemical marker; this can be helpful in cases where CD25 is negative. CD34 staining may also be obtained to quantify whether the proportion of myeloblasts are increased, especially in SM-AHN cases, eg, SM associated with MDS, MPN, MDS/MPN, CEL, NOS, or AML.
- Reticulin and collagen staining should also be undertaken to assess the grade of bone marrow fibrosis (eg, MF-0 to MF-3), which is relatively common in advanced SM >ISM/SSM, particularly in areas of mast cell aggregates.
- Flow cytometry is a complementary tool in the diagnosis or monitoring of mast cell disease. CD117, CD25, and CD2 are standard flow markers; testing for CD30 can also be considered. Flow cytometric characterization of mast cells comprises rare event analyses; optimal techniques for characterization and enumeration of neoplastic mast cells are described in the literature.<sup>1-3</sup>
- Chromosome analysis should be obtained in the workup of systemic mastocytosis, especially in cases with a suspected AHN.
- Myeloid mutation panel testing should be performed on the bone marrow, but can be performed on the peripheral blood in the presence of an AHN and/or circulating mast cells. Myeloid mutation panels alone are not recommended for the detection of *KIT* D816V. Next-generation sequencing (NGS) assays can exhibit low sensitivity and higher-sensitivity assays should always be performed.

[KIT D816V Mutation Testing on SM-G 2 of 3.](#)[See References on SM-G 3 of 3.](#)<sup>a</sup>Well-differentiated SM is a morphologic variant present in all subtypes of SM.**Note:** All recommendations are category 2A unless otherwise indicated.**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**RECOMMENDATIONS FOR HISTOPATHOLOGY ANALYSIS AND *KIT* D816V MUTATION TESTING*****KIT* D816V MUTATION TESTING<sup>4</sup>**

- If a diagnosis of SM is suspected, molecular testing for *KIT* D816V using an assay with high sensitivity (eg, ASO-qPCR or digital droplet PCR)<sup>b,5</sup> can first be undertaken on the peripheral blood, in combination with measurement of the serum tryptase level and evaluation of clinical signs and/or symptoms suggestive of SM-related organ involvement.
- Following a positive test on peripheral blood, *KIT* mutational analysis may also be performed on the bone marrow aspirate. Fresh bone marrow aspirate is preferable but formalin-fixed paraffin-embedded tissue can also be used. Decalcified tissue typically interferes with DNA/RNA assays, and thus, decalcified BM should not be used for mutational analysis. If initial screening of the peripheral blood fails to detect the *KIT* D816V mutation in a patient with suspected SM, testing of the bone marrow should be undertaken with a highly sensitive assay (eg, ASO-qPCR or digital droplet PCR).
- When applied to the bone marrow, these assays can detect the *KIT* D816V mutation in >80% of patients with SM, a sensitivity that is considered sufficient in daily practice for routine diagnostic screening of SM. In cases of a suboptimal bone marrow aspirate (eg, dry tap), testing of the peripheral blood should be undertaken as an alternative option for detection of *KIT* D816V mutation.
- In <5%–10% of patients, no *KIT* D816V mutation is detected. This may be due to: 1) patients are in fact *KIT* D816V positive, but the (very) low mast cell burden leads to a false-negative result because the sensitivity of the applied assay is too low and/or the tissue sample is suboptimal; 2) patients indeed only bear wild-type *KIT*; or 3) patients are positive for other mutations at codon 816 (D816H, D816Y, others) or in other regions of *KIT* that are not detectable by high-sensitivity assays (eg, ASO-qPCR or digital droplet PCR). In patients with low mast cell burden ISM who are otherwise negative for *KIT* D816V mutation, evaluation for *KIT* D816V mutation in the skin or from an extracutaneous organ besides the bone marrow could be considered.
- In patients with a high mast cell burden and a negative *KIT* D816V screen, the result should be confirmed with the most sensitive technique available (eg, ASO-qPCR or digital droplet PCR), if not originally obtained with this technique. If *KIT* D816V mutation is still negative, this should be followed by evaluation of *KIT* for alternative codon 816 mutations, which requires amplification of codon 17 and sequencing of the resulting amplicons, or preferably peptide nucleic acid (PNA)-mediated PCR.
- If no mutation is found at codon 816, sequencing of the whole *KIT* coding sequence by NGS may be undertaken. However, the sensitivity of myeloid gene mutation panels for detection of *KIT* mutations is relatively lower, at ~5%.
- In patients with low mast cell burden ISM and a stable, clinical course, evaluation of *KIT* D816V allele burden (if available) should be considered at diagnosis, but should not necessarily be repeated, unless signs of disease progression occur.
- In patients with more aggressive forms of SM, and those enrolled in clinical trials involving cytoreductive therapies, evaluation of *KIT* D816V allele burden (if available) by high-sensitivity assays (eg, ASO-qPCR or digital droplet PCR) on DNA or on RNA/cDNA should be considered before initiating therapy and serially during therapy.

<sup>b</sup>In the absence of a highly sensitive quantitative PCR assay, qualitative PCR can be used.[See References on SM-G 3 of 3](#)**Note:** All recommendations are category 2A unless otherwise indicated.**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.





### RECOMMENDATIONS FOR HISTOPATHOLOGY ANALYSIS AND *KIT* D816V MUTATION TESTING

### REFERENCES

- <sup>1</sup>Escribano L, Garcia Montero AC, Nunez R, et al. Flow cytometric analysis of normal and neoplastic mast cells: role in diagnosis and follow-up of mast cell disease. *Immunol Allergy Clin North Am* 2006;26:535-547.
- <sup>2</sup>Sánchez-Muñoz L, Teodosio C, Morgado JM, et al. Flow cytometry in mastocytosis: utility as a diagnostic and prognostic tool. *Immunol Allergy Clin North Am* 2014;34:297-313.
- <sup>3</sup>Teodosio C, Mayado A, Sánchez-Muñoz L, et al. The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis. *J Leukoc Biol* 2015;97:49-59.
- <sup>4</sup>Arock M, Sotlar K, Akin C, et al. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. *Leukemia* 2015;29(6):1223-1232.
- <sup>5</sup>Greiner G, Gurbisz M, Ratzinger F, et al. Digital PCR: A sensitive and precise method for *KIT* D816V quantification in mastocytosis. *Clin Chem* 2018;64:547-55.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



### ADVERSE PROGNOSTIC VARIABLES AND RISK STRATIFICATION

#### ADVERSE PROGNOSTIC VARIABLES IN SYSTEMIC MASTOCYTOSIS ([SM-H, 2 of 5](#))

#### RISK STRATIFICATION FOR PATIENTS WITH SYSTEMIC MASTOCYTOSIS

MARS	( <a href="#">SM-H, 3 of 5</a> )
MAPS	( <a href="#">SM-H, 3 of 5</a> )
IPSM	( <a href="#">SM-H, 4 of 5</a> )
GPSM	( <a href="#">SM-H, 5 of 5</a> )

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**ADVERSE PROGNOSTIC VARIABLES IN SYSTEMIC MASTOCYTOSIS****Clinical/Laboratory Variables**

- WHO subclassification of SM<sup>1</sup>
- Advanced age, history of weight loss, anemia, thrombocytopenia, hypoalbuminemia, and excess bone marrow blasts (>5%)<sup>1</sup>
- Eosinophilia<sup>2,3,a</sup>
- Splenomegaly<sup>4</sup>
- Increased alkaline phosphatase<sup>4</sup>

**Cytogenetic/Molecular Variable**

- Poor-risk karyotype (monosomy 7 or complex karyotype)<sup>5</sup>
- Multilineage involvement of *KIT* D816V mutation<sup>6</sup>
- Number of non-*KIT* D816V mutations<sup>7</sup>
- *SRSF2/ASXL1/RUNX1* (S/A/R), and/or *EZH2* or *ASXL1/CBL* mutation profile<sup>4,5,7-10</sup>

**Footnotes**

<sup>a</sup>Patients who are *KIT* D816V mutation negative or who exhibit eosinophilia with the *FIP1L1-PDGFR*A fusion gene have a good prognosis.

**References**

- <sup>1</sup>Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. *Blood* 2009;113:5727-5736.
- <sup>2</sup>Bohm A, Födinger M, Wimazal F, et al. Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance *J Allergy Clin Immunol* 2007;120:192-199.
- <sup>3</sup>Kluin-Nelemans HC, Reiter A, Illerhaus A et al. Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. *Leukemia* 2020;34(4):1090-1101.
- <sup>4</sup>Jawhar M, Schwaab J, Hausmann D, et al. Splenomegaly, elevated alkaline phosphatase and mutations in the *SRSF2/ASXL1/RUNX1* gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. *Leukemia* 2016;30:2342-2350.
- <sup>5</sup>Naumann N, Jawhar M, Schwaab J, et al. Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis. *Genes Chromosomes Cancer* 2018;57(5):252-259.
- <sup>6</sup>Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. *KIT* mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. *Blood* 2006;108:2366-2372.
- <sup>7</sup>Schwaab J, Schnittger S, Sotlar K, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. *Blood* 2013;122:2460-2466.
- <sup>8</sup>Jawhar M, Schwaab J, Schnittger S, et al. Additional mutations in *SRSF2*, *ASXL1* and/or *RUNX1* identify a high-risk group of patients with *KIT* D816V(+) advanced systemic mastocytosis. *Leukemia* 2016;30:136-143.
- <sup>9</sup>Pardanani AD, Lasho TL, Finke C, et al. *ASXL1* and *CBL* mutations are independently predictive of inferior survival in advanced systemic mastocytosis. *Br J Haematol* 2016;175:534-536.
- <sup>10</sup>Muñoz-González JI, Jara-Acevedo M, Alvarez-Twose I et al. Impact of somatic and germline mutations on the outcome of systemic mastocytosis. *Blood Adv* 2018;2(21):2814-2828.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**



# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

### RISK STRATIFICATION FOR PATIENTS WITH SYSTEMIC MASTOCYTOSIS

#### MUTATION-ADJUSTED RISK SCORE (MARS) FOR ADVANCED SYSTEMIC MASTOCYTOSIS<sup>11</sup>

Prognostic Variable	Points
Age >60 years	1
Hemoglobin <10 g/dL	1
Platelets <100 x 10 <sup>9</sup> /L	1
One S/A/R ( <i>SRSF2</i> , <i>ASXL1</i> , or <i>RUNX1</i> ) mutation	1
≥2 S/A/R mutation	2

Risk Group	Points
Low	0 to 1
Intermediate	2
High	3 or 5

#### MAYO ALLIANCE PROGNOSTIC SYSTEM (MAPS) FOR MASTOCYTOSIS<sup>12</sup>

Prognostic Variable	Points
Age >60 years	1
Advanced SM vs. ISM/SSM	2
Platelets <150 x 10 <sup>9</sup> /L	1
Serum alkaline phosphatase (ALP) > normal range	1
Adverse mutation ( <i>ASXL1</i> , <i>RUNX1</i> , and <i>NRAS</i> )	1

Risk Group	Points
Low	≤2
Intermediate-1	3
Intermediate-2	4
High	≥5

<sup>11</sup>Jawhar M, Schwaab J, Alvarez-Twose I, et al. MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis. J Clin Oncol 2019;37:2846-2856.

<sup>12</sup>Pardanani A, Shah S, Mannelli F, et al. Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. Blood Adv 2018;2:2964-2972.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



### RISK STRATIFICATION FOR PATIENTS WITH SYSTEMIC MASTOCYTOSIS

#### INTERNATIONAL PROGNOSTIC SCORING SYSTEM FOR MASTOCYTOSIS (IPSM) SCORE FOR NON-ADVANCED SYSTEMIC MASTOCYTOSIS<sup>13</sup>

Prognostic Variable	Points
Age ≥60 years	1
Alkaline phosphatase ≥100 U/L	1

Risk Group	Points
Low-risk	0
Intermediate-risk group 1 (Int-1)	1
Intermediate-risk group 2 (Int-2)	2

#### IPSM SCORE FOR ADVANCED SYSTEMIC MASTOCYTOSIS<sup>13</sup>

Prognostic Variable	Points
Age ≥60 years	1
Tryptase ≥125 ng/mL	1
Leukocytes ≥16 × 10 <sup>9</sup> /L	1
Hemoglobin ≤11 g/dL	1
Platelets ≤100 × 10 <sup>9</sup> /L	1
Skin involvement	-1

Risk Group	Points
Advanced SM 1 (AdvSM-1)	-1 to 0
Advanced SM 2 (AdvSM-2)	1
Advanced SM 3 (AdvSM-3)	2–3
Advanced SM 4 (AdvSM-4)	4 or 5

<sup>13</sup>Sperr WR, Kundi M, Alvarez-Twose I, et al. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. Lancet Haematol 2019;6:e638-e649.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.





# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

### RISK STRATIFICATION FOR PATIENTS WITH SYSTEMIC MASTOCYTOSIS

#### GLOBAL PROGNOSTIC SCORE MODEL FOR PROGRESSION-FREE SURVIVAL (GPSM-PFS)<sup>14</sup>

Prognostic Variable	Points
Hemoglobin ≤11 g/dL	-
Platelet count ≤100 x 10 <sup>9</sup> /L	1
Serum alkaline phosphatase ≥140 IU/L	-
Serum baseline tryptase ≥125 µg/L	2
Serum β2-microglobulin ≥2.5 µg/mL	3.5
Presence of <i>SRSF2</i> , <i>ASXL1</i> , <i>RUNX1</i> , <i>DNMT3A</i> gene mutations	-

Risk group	Points
Low risk	0
Intermediate risk	1–3.5
High risk	>3.5

#### GLOBAL PROGNOSTIC SCORE MODEL FOR OVERALL SURVIVAL (GPSM-OS)<sup>14</sup>

Prognostic Variable	Points
Hemoglobin ≤11 g/dL	1
Platelet count ≤100 x 10 <sup>9</sup> /L	-
Serum alkaline phosphatase ≥140 IU/L	1.5
Serum baseline tryptase ≥125 µg/L	-
Serum β2-microglobulin ≥2.5 µg/mL	-
Presence of <i>SRSF2</i> , <i>ASXL1</i> , <i>RUNX1</i> , <i>DNMT3A</i> gene mutations	1

Risk group	Points
Low risk	0
Intermediate risk	1–1.5
High risk	≥2

<sup>14</sup>Muñoz-González JI, Álvarez-Twose I, Jara-Acevedo M, et al. Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. The Lancet Haematol 2021;8:e194-e204.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



### SIGNS AND SYMPTOMS OF MAST CELL ACTIVATION<sup>a,b</sup>

- **Anaphylaxis**
- **Fatigue**
- **Light-headedness, syncope/fainting**
- **Skin:**
  - Flushing of the face, neck, and chest
  - Pruritus, itching, +/- rash
  - Hives, with or without angioedema (swelling) skin rashes
- **Gastrointestinal:**
  - Gastric distress, diarrhea, nausea, vomiting, abdominal pain, bloating, gastroesophageal reflux disease (GERD)
- **Neuropsychiatric symptoms**
  - Headache and/or brain fog, cognitive dysfunction, anxiety, depression, short memory span, inability to concentrate
- **Cardiovascular:**
  - Rapid heart rate, chest pain
  - Low blood pressure, high blood pressure at the start of a reaction, blood pressure instability
- **Pulmonary:**
  - Wheezing and shortness of breath
- **Musculoskeletal:**
  - Bone/muscle pain, osteosclerosis, osteopenia, osteoporosis
- **Nasal/throat:**
  - Nasal itching and congestion
  - Throat itching and swelling

### POTENTIAL TRIGGERS OF MAST CELL ACTIVATION

- **Heat, cold, or sudden temperature changes**
- **Sun/sunlight**
- **Natural and chemical odors**
- **Food or beverages, including alcohol**
- **Insect stings**
- **Venoms (eg, hymenoptera, spiders, fire ants, jellyfish, snakes)**
- **Infections (viral, bacterial, or fungal)**
- **Stress: emotional; physical, including pain; or environmental (eg, weather changes, pollution, pollen, pet dander)**
- **Lack of sleep/sleep deprivation**
- **Exercise**
- **Drugs (ie, opioids, NSAIDs, some antibiotics [eg, vancomycin, some local/general anesthetics]) and contrast dyes**
- **Vaccinations**
- **Mechanical irritation, friction, or vibration**
- **Surgery**
- **Procedures (eg, endoscopy, colonoscopy)**

<sup>a</sup>Specific criteria have been established for primary and secondary MCAS (Akin C. Mast cell activation syndromes. J Allergy Clin Immunol 2017;140:349-355). Primary MCAS has also been referred to as monoclonal mast cell activation syndrome (MMAS). ([See Discussion](#)).

<sup>b</sup>From The Mastocytosis Society website: <https://tmsforacure.org/symptoms/symptoms-and-triggers-of-mast-cell-activation/>

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**ANTI-MEDIATOR DRUG THERAPY APPROACHES FOR MAST CELL ACTIVATION SYMPTOMS<sup>a,b</sup>****Avoidance of Triggers**

- Specific foods, medications, allergens, and general triggers
- Physical measures
  - Avoid sudden changes in temperature
  - Avoid extreme temperatures in bath/shower, swimming pool, or air conditioning
  - Avoid dryness of skin
  - Avoid rubbing

**Skin Care**

- Take steps to avoid dryness of skin
- Use skin moisturizer
- Topical cromolyn sodium (water-soluble cream 1%–4%):<sup>c</sup> apply two to four times a day for urticaria, pruritus, vesicles, or bullae. Do not use on denuded lesions (consider topical antibiotics).
- Topical corticosteroids
- Diffuse lesions: apply bath or sterile gauze with zinc sulfate

**Solitary Mastocytoma**

- Topical cromolyn sodium (water-soluble cream 1%–4%):<sup>c</sup>
- Topical corticosteroid
- Avoid friction and pressure
- Consider surgical excision (ie, flexures, soles, palms, scalp)

**Urticaria Pigmentosa and Other Forms**

- Trigger(s)-related symptoms
  - Avoidance of triggers
  - Non-sedating H1 antihistamines
  - H2 antihistamines
  - Topical cromolyn sodium (cream/ointment 1%–4%):<sup>c</sup>
- Continuous moderate symptoms
  - Scheduled non-sedating H1 antihistamines
    - ◊ Add sedating H1 antihistamines on demand
  - Scheduled or on-demand H2 antihistamines
  - Scheduled topical cromolyn sodium (cream/ointment 1%–4%):<sup>c</sup>
- Severe symptoms
  - Scheduled non-sedating H1 antihistamines
  - Scheduled sedating H1 antihistamines
  - Scheduled H2 antihistamines
  - Add anti-leukotrienes in refractory cases

**Diffuse Forms with Life-Threatening Mast Cell-Mediated Related Symptoms, Bullae, and Blistering**

- Treatment may require hospitalization
- Sterile conditions
- Topical cromolyn sodium (cream/ointment 1%–4%):<sup>c</sup>
- Topical corticosteroids
- Zinc sulfate
- Oral corticosteroids

<sup>a</sup>Specific criteria have been established for primary and secondary MCAS (Akin C. Mast cell activation syndromes. J Allergy Clin Immunol 2017;140:349-355). Primary MCAS has also been referred to as MMAS. ([See Discussion](#)).

<sup>b</sup>Castells M, Butterfield J. Mast cell activation syndrome and mastocytosis: Initial treatment options and long-term management. J Allergy Clin Immunol Pract 2019;4:1097-1106.

<sup>c</sup>Available as a compounded agent.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**Continued**

**SM-J**  
**1 OF 4**



### STEPWISE PROPHYLACTIC TREATMENT APPROACH FOR CHRONIC MAST CELL MEDIATOR-RELATED SYMPTOMS

Organ Involvement/Symptoms	Stepwise Treatment <sup>d,e</sup>
<b>Skin:</b> Pruritus, flushing, urticaria, angioedema dermatographism	<ol style="list-style-type: none"> <li>1. H1 blockers and H2 blockers</li> <li>2. Leukotriene receptor antagonist</li> <li>3. Aspirin</li> <li>4. Ketotifen<sup>c</sup></li> <li>5. Topical cromolyn sodium (cream/ ointment 1%–4%)<sup>c</sup></li> </ol>
<b>Gastrointestinal:</b> Diarrhea, abdominal cramping, nausea, vomiting	<ol style="list-style-type: none"> <li>1. H2 blockers</li> <li>2. Cromolyn sodium</li> <li>3. Proton pump inhibitors</li> <li>4. Leukotriene receptor antagonist</li> <li>5. Ketotifen<sup>c</sup></li> </ol>
<b>Neurologic:</b> Headache, poor concentration and memory, brain fog	<ol style="list-style-type: none"> <li>1. H1 blockers and H2 blockers</li> <li>2. Cromolyn sodium</li> <li>3. Aspirin</li> <li>4. Ketotifen<sup>c</sup></li> </ol>
<b>Cardiovascular:</b> Pre-syncope, tachycardia	<ol style="list-style-type: none"> <li>1. H1 blockers and H2 blockers</li> <li>2. Corticosteroids</li> <li>3. Omalizumab</li> </ol>
<b>Pulmonary:</b> Wheezing, throat swelling	<ol style="list-style-type: none"> <li>1. H1 blockers and H2 blockers</li> <li>2. Corticosteroids</li> <li>3. Omalizumab</li> </ol>
<b>Naso-ocular:</b> Nasal stuffiness, nasal pruritus, conjunctival injection	<ol style="list-style-type: none"> <li>1. H1 blockers</li> <li>2. Corticosteroids</li> <li>3. Cromolyn sodium</li> </ol>

<sup>c</sup>Available as a compounded agent.

<sup>d</sup>Standard doses need to be titrated. Higher doses may be necessary for symptoms refractory to standard-dose treatment.

<sup>e</sup>The use of these medications in a stepwise treatment plan may vary according to the specific patient scenarios.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)



# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

### ACUTE TREATMENT OF ANAPHYLAXIS<sup>1-7</sup> (Includes hymenoptera venom anaphylaxis)

Indication	Treatment
<b>Systemic hives</b>	<b>Antihistamines (H1 blockers and H2 blockers)</b>
<b>Systemic hives + second organ involved in an acute onset reaction (eg, upper/lower airway, gastrointestinal, neurologic, cardiovascular)</b>	<b>Epinephrine intramuscular (IM)</b> (repeat up to 3 times every 5 minutes in the absence of clinical improvement) <b>IV Epinephrine after 3 doses of epinephrine IM</b>
<b>Acute onset of anaphylaxis with the following symptoms:</b> <ul style="list-style-type: none"> <li>• Hypotension</li> <li>• Laryngeal edema</li> <li>• Vasomotor collapse</li> <li>• Oxygen desaturation</li> <li>• Seizures</li> </ul>	<b>Epinephrine (IM)</b> (repeat up to 3 times every 5 minutes in the absence of clinical improvement) <b>IV Epinephrine after 3 doses of epinephrine IM</b>
<b>Complementary treatments (in addition to antihistamines)</b> <ul style="list-style-type: none"> <li>• IV fluids</li> <li>• Oxygen</li> <li>• Consider glucagon (if anaphylaxis related to <math>\beta</math>-adrenergic receptor blockade)</li> <li>• Antihistamines such as diphenhydramine (25 mg every 2–4 h up to 100 mg/24 h) should be considered before starting corticosteroid therapy</li> <li>• Corticosteroids (0.5–1 mg/kg)</li> <li>• Consider bradykinin inhibitor (if anaphylaxis due to ACE inhibitor)</li> </ul>	

### PREVENTION OF ANAPHYLAXIS<sup>1-7</sup>

Indication	Treatment
• Hymenoptera-specific IgE or skin test positive	<b>Venom immunotherapy</b> <b>Rush desensitization (may be available only in selected centers)</b>
<ul style="list-style-type: none"> <li>• Unprovoked anaphylaxis</li> <li>• Hymenoptera or food-induced, with negative specific IgE or negative skin test</li> <li>• To improve tolerance while on immunotherapy</li> </ul>	<b>Omalizumab<sup>8-10</sup></b>

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)





### TREATMENT FOR OSTEOPENIA/OSTEOPOROSIS<sup>11,12</sup>

- **Supplemental calcium and vitamin D**
- **Bisphosphonates (with continued use of antihistamines)**
  - **May resolve bone pain and improve vertebral bone mineral density (more than femoral head bone mineral density)**
- **Peginterferon alfa-2a**
  - **Consider for patients with refractory bone pain and/or worsening bone mineral density on bisphosphonate therapy**
- **Anti-RANKL monoclonal antibody (eg, denosumab)**
  - **Generally used as second-line therapy for patients with bone pain not responding to bisphosphonates or for patients who are not candidates for bisphosphonates because of renal insufficiency**
- **Vertebroplasty/kyphoplasty for refractory pain associated with vertebral compression fractures in selected patients**

#### References

- <sup>1</sup>Bonadonna P, Zanotti R, Muller U. Mastocytosis and insect venom allergy. *Curr Opin Allergy Clin Immunol* 2010;10:347-353.
- <sup>2</sup>Gonzalez de Olano D, Alvarez-Twose I, Esteban-Lopez MI, et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. *J Allergy Clin Immunol* 2008;121:519-526.
- <sup>3</sup>Bonadonna P, Gonzalez de Olano D, Zanotti R, et al. Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations. *J Allergy Clin Immunol Pract* 2013;1:474-478.
- <sup>4</sup>Carter MC, Robyn JA, Bressler PB, et al. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. *J Allergy Clin Immunol* 2007;119:1550-1551.
- <sup>5</sup>Castells MC, Hornick JL, Akin C. Anaphylaxis after hymenoptera sting: is it venom allergy, a clonal disorder, or both? *J Allergy Clin Immunol Pract* 2015;3:350-355.
- <sup>6</sup>Castells MC. A new era for drug desensitizations. *J Allergy Clin Immunol Pract* 2015;3:639-640.
- <sup>7</sup>Jimenez-Rodriguez TW, Garcia-Neuer M, Alenazy LA, Castells M. Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers. *J Asthma Allergy* 2018;11:121-142.
- <sup>8</sup>Slapnickar C, Trinkaus M, Hicks L, Vadas P. Efficacy of omalizumab in indolent systemic mastocytosis. *Case Rep Hematol* 2019;2019:3787586.
- <sup>9</sup>Distler M, Maul JT, Steiner UC, et al. Efficacy of omalizumab in mastocytosis: Allusive indication obtained from a prospective, double-blind, multicenter study (XOLMA Study). *Dermatology* 2020;236:529-539.
- <sup>10</sup>Jendoubi F, Gaudenzio N, Gallini A, et al. Omalizumab in the treatment of adult patients with mastocytosis: a systematic review. *Clin Exp Allergy* 2020;50:654-661.
- <sup>11</sup>Orsolini G, Gavioli I, Tripi G, et al. Denosumab for the treatment of mastocytosis-related osteoporosis: a case series. *Calcif Tissue Int* 2017;100:595-598.
- <sup>12</sup>Rossini M, Zanotti R, Orsolini G, et al. Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis. *Osteoporos Int* 2016;27:2411-2421.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**SPECIAL CONSIDERATIONS FOR THE MANAGEMENT OF PATIENTS WITH SYSTEMIC MASTOCYTOSIS****Surgery<sup>1-5</sup>**

- Risk of anaphylaxis in the perioperative period is estimated to be higher in patients with SM relative to the the general population, but anesthesia is not contraindicated in patients with SM.
- Multidisciplinary management is recommended with the involvement of surgical, anesthesia, and perioperative medical teams.
- Mast cell activation can occur from IgE-related or IgE-unrelated mechanisms. The primary goal of management is to prevent mast cell activation during and in the immediate aftermath of the surgical procedure.
- Careful review of prior anesthetic records and identification/avoidance of known triggers of mast cell activation are critical.
- Temperature extremes (hypothermia or hyperthermia) and unnecessary trauma (eg, with patient positioning) that could lead to mast cell activation symptoms, skin blistering, or osteolytic fractures should be avoided in the operating room.
- Pre-anesthetic treatment is probably helpful in reducing the frequency and/or severity of mast cell activation events. This includes the use of anxiolytic agents (eg, benzodiazepines), antihistamines (H1 and H2 blockers), and possibly corticosteroids, which can help in resolution of mast cell activation symptoms.
- Certain perioperative drugs are considered safer, although the supporting data are anecdotal and not evidence based. These include certain anesthetic induction (propofol) or inhalational (sevoflurane or isoflurane) agents, analgesics (fentanyl or remifentanyl), local anesthetics (lidocaine, bupivacaine), and skin antiseptics (povidone iodine).
- Agents to be avoided include the muscle relaxants atracurium and mivacurium (rocuronium and vecuronium may be safer) and succinylcholine. While caution should be exercised with opiates (eg, codeine or morphine), it is important, however, that analgesics not be withheld from patients with SM since pain can be a trigger for mast cell activation.
- Management of mast cell activation symptoms depends upon their severity, and relies upon discontinuation of the suspected drug or anesthetic agent, fluid resuscitation, and intravenous epinephrine for severe reactions. Corticosteroids and antihistamines (H1 and H2 blockers) may be used as adjuncts.
- In the event of anaphylaxis or other mast cell activation event, a full allergic workup should be initiated. Serum tryptase level should be checked within 30–120 minutes of onset of symptoms. Measurement of baseline serum tryptase level after full recovery is an important comparator. Identification of IgE-mediated hypersensitivity to drugs or latex requires detection of specific IgE and skin testing (skin prick and intradermal tests).

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)**SM-K**  
**1 OF 4**

**SPECIAL CONSIDERATIONS FOR THE MANAGEMENT OF PATIENTS WITH SYSTEMIC MASTOCYTOSIS****Pregnancy**<sup>6-15</sup>

- Based on a paucity of studies, insufficient evidence currently exists regarding whether a diagnosis of SM results in significantly increased rates of adverse maternal or fetal outcomes (eg, spontaneous miscarriage, preterm infants, complications of labor and delivery) compared to the general population.
- A diagnosis of SM does not appear to affect fertility.
- Pre-conception, pregnancy, and the peripartum period should be managed by a multidisciplinary team, including high-risk obstetrics, anesthesia, and allergy.
- Management of SM during pregnancy involves alleviation of symptoms related to mast cell activation and titration of acceptable medications to minimize potential harm to the fetus.
- Avoidance of triggers, prophylactic use of antihistamines, as-needed corticosteroids, and epinephrine on demand for anaphylaxis are standard approaches during pregnancy. Please refer to the table for medications used to treat mastocytosis and their potential risks during both pregnancy and lactation ([SM-K 3 of 4](#)).
- For severe cases of SM during pregnancy refractory to conventional therapy, cytoreductive therapy with peginterferon alfa-2a can be considered. Use of cladribine or tyrosine kinase inhibitors (eg, imatinib, midostaurin, avapritinib) is not recommended. There are not sufficient data to establish the use of peginterferon alfa-2a (risk category C) in pregnancy. It should be used only if benefits outweigh potential risk to the fetus.<sup>15</sup>

**References**

- Matito A, Morgado JM, Sanchez-Lopez P, et al. Management of anesthesia in adult and pediatric mastocytosis: A study of the Spanish Network on Mastocytosis (REMA) based on 726 anesthetic procedures. *Int Arch Allergy Immunol* 2015;167(1):47-56.
- Pardanani A. How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). *Blood* 2013;121(16):3085-3094.
- Dewachter P, Castells MC, Hepner DL, Mouton-Faivre C. Perioperative management of patients with mastocytosis. *Anesthesiology* 2014;120(3):753-759.
- Mastocytosis and anaesthesia advice for patients: <https://www.rcoa.ac.uk/sites/default/files/documents/2019-09/Mastocytosis2014.pdf>.
- Castells M, Butterfield J. Mast cell activation syndrome and mastocytosis: Initial treatment options and long-term management. *J Allergy Clin Immunol Pract* 2019;4:1097-1106.
- Lei D, Akin C, Kovalszki A. Management of mastocytosis in pregnancy: a review. *J Allergy Clin Immunol Pract* 2017;5:1217-1223.
- Madendag IC, Madendag Y, Tarhan I, Altinkaya SO, et al. Mastocytosis in pregnancy. *Taiwan J Obstet Gynecol* 2010;49:192-196.
- Woidacki K, Zenclussen AC, Siebenhaar F. Mast cell-mediated and associated disorders in pregnancy: a risky game with an uncertain outcome? *Front Immunol* 2014;5:231.
- Donahue JG, Lupton JB, Golichowski AM. Cutaneous mastocytosis complicating pregnancy. *Obstet Gynecol* 1995;85:813-815.
- Ciach K, Niedoszytko M, Abacjew-Chmylko A, et al. Pregnancy and delivery in patients with mastocytosis treated at the Polish Center of the European Competence Network on Mastocytosis (ECNM). *PLoS One* 2016;11:e0146924.
- Matito A, Álvarez-Twose I, Morgado JM, et al. Clinical impact of pregnancy in mastocytosis: a study of the Spanish Network on Mastocytosis (REMA) in 45 cases. *Int Arch Allergy Immunol* 2011;156:104-11.
- Worobec AS, Akin C, Scott LM, Metcalfe DD. Mastocytosis complicating pregnancy. *Obstet Gynecol* 2000;95:391-395.
- Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. *Lancet* 2012;379:2162-72.
- Beauverd Y, Radia D, Cargo C, et al. Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series. *Haematologica* 2016;101:e182-e184.

**Note: All recommendations are category 2A unless otherwise indicated.****Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**



# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

### SPECIAL CONSIDERATIONS FOR THE MANAGEMENT OF PATIENTS WITH SYSTEMIC MASTOCYTOSIS<sup>a</sup>

Table 1. Mastocytosis Treatments and Pregnancy / Lactation Risk<sup>b</sup>

Group	Medication	Risk Category	Pregnancy Implication	Lactation Implications
First-generation H1 antihistamines	Brompheniramine	C	Increased risk of birth defects	Use with caution
	Chlorpheniramine	C	No increased risk of birth defects	Excreted in breast milk, use with caution
	Dimenhydrinate	B	Crosses placenta, no increased risk of fetal abnormalities	Excreted in breast milk, use with caution
	Diphenhydramine	B	Cross placenta, unclear historical association with cleft palate	Excreted in breast milk, breastfeeding contraindicated
	Doxylamine	C	Historical association with neural tube defects, oral clefts, hypoplastic left heart	Breastfeeding contraindicated
	Hydroxyzine	C	Crosses placenta, no increased risk of birth defects but not recommended in early pregnancy	Breastfeeding not recommended
	Meclizine	B	No increased risk of birth defects	Unknown if excreted into breast milk
Second-generation H1 antihistamines	Cetirizine	B	No increased risk of birth defects	Excreted in breast milk
	Levocetirizine	B	No increased risk of birth defects	Unknown if excreted into breast milk, not recommended
	Loratadine	B	No increased risk of birth defects, prior historical association with hypospadias	Small amounts excreted into breast milk
	Fexofenadine	C	Limited information available	Excreted in breast milk
	Desloratadine	C	Adverse side effects in animal studies	Excreted in breast milk
H2 antihistamines	Cimetidine	B	Crosses placenta, no increased risk of birth defects	Excreted in breast milk, breastfeeding not recommended
	Famotidine	B	Crosses placenta, no increased risk of birth defects	Excreted in breast milk, use with caution
Mast cell stabilizer	Cromolyn	B	Safe in pregnancy	No data on excretion into breast milk, use with caution
	Ketotifen	C	Adverse events in animal studies	Breastfeeding not recommended
Anti-IgE antibody	Omalizumab	B	No increased risk of birth defects	Likely excreted in breast milk, not recommended

Category A: The safest drugs to take during pregnancy. No known adverse reactions. Category C: Not enough research has been done to determine if these drugs are safe. Category B: No risks have been found in humans. Category D: Adverse reactions have been found in humans.

<sup>a</sup>Kar S, Krishnan A, Preetha K, Mohankar A. A review of antihistamines used during pregnancy. J Pharmacol Pharmacother 2012;3(2):105-108.

<sup>b</sup>Breastfeeding by patients with SM should be done in consultation with a pediatrician and International Board Certified Lactation Consultant (IBCLC).

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)



### SPECIAL CONSIDERATIONS FOR THE MANAGEMENT OF PATIENTS WITH SYSTEMIC MASTOCYTOSIS<sup>a</sup>

Table 1. (continued) Mastocytosis Treatments and Pregnancy / Lactation Risk<sup>b</sup>

Group	Medication	Risk Category	Pregnancy Implications	Lactation Implications
Glucocorticoids	Hydrocortisone	C	Increased risk of oral clefts with use in the first trimester	Excreted in breast milk, wait 4 h after dose
	Prednisone	C/D	Increased risk of oral clefts with use in the first trimester	Excreted in breast milk
	Betamethasone	C	Increased risk of oral clefts with use in the first trimester, nonfluorinated corticosteroid preferred	Excreted in breast milk, wait 4 h after dose
	Dexamethasone	C	Increased risk of oral clefts with use in the first trimester, nonfluorinated corticosteroid preferred	Excreted in breast milk, wait 4 h after dose
Leukotriene receptor antagonist	Montelukast	B	No increased risk of birth defects	Unknown if excreted into breast milk, use with caution
Cytoreductive therapies	Cladribine	D	Teratogenic effects and fetal mortality observed	Not recommended
	Imatinib	D	Pregnancy not recommended (in mother or father) within 2 wk of last imatinib dose	Not recommended

Category A: The safest drugs to take during pregnancy. No known adverse reactions.

Category B: No risks have been found in humans.

Category C: Not enough research has been done to determine if these drugs are safe.

Category D: Adverse reactions have been found in humans.

<sup>a</sup>Kar S, Krishnan A, Preetha K, Mohankar A. A review of antihistamines used during pregnancy. J Pharmacol Pharmacother 2012;3(2):105-108.

<sup>b</sup>Breastfeeding by patients with SM should be done in consultation with a pediatrician and IBCLC.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.





### MANAGEMENT OF MIDOSTAURIN TOXICITY<sup>1</sup>

- The starting dose of midostaurin is 100 mg twice daily with food.
- Co-administration of midostaurin with strong CYP3A inhibitors may increase midostaurin concentrations. Consider alternative concomitant therapies that do not strongly inhibit CYP3A activity.

#### Hematologic Toxicities:

- ANC  $<1 \times 10^9/L$  attributed to midostaurin in patients without MCL, or ANC  $<0.5 \times 10^9/L$  attributed to midostaurin in patients with baseline ANC value of  $0.5\text{--}1.5 \times 10^9/L$ : Interrupt midostaurin until ANC  $>1 \times 10^9/L$ , then resume midostaurin at 50 mg twice daily, and if tolerated, increase to 100 mg twice daily. Discontinue midostaurin if low ANC persists for  $>21$  days and is suspected to be related to midostaurin.
- Platelet count  $<50 \times 10^9/L$  attributed to midostaurin in patients without MCL, or platelet count  $<25 \times 10^9/L$  attributed to midostaurin in patients with baseline platelet count of  $25\text{--}75 \times 10^9/L$ : Interrupt midostaurin until platelet count  $>50 \times 10^9/L$ , then resume midostaurin at 50 mg twice daily, and if tolerated, increase to 100 mg twice daily. Discontinue if low platelet count persists for  $>21$  days and is suspected to be related to midostaurin.
- Hemoglobin  $<8$  g/dL attributed to midostaurin in patients without MCL, or life-threatening anemia attributed to midostaurin in patients with baseline hemoglobin value of  $8\text{--}10$  g/dL. Interrupt midostaurin until hemoglobin  $>8$  g/dL, then resume midostaurin at 50 mg twice daily, and if tolerated, increase to 100 mg twice daily. Discontinue if low hemoglobin persists for  $>21$  days and is suspected to be related to midostaurin.

#### Non-Hematologic Toxicities:

- Grade 3/4 nausea and/or vomiting despite optimal antiemetic therapy: Interrupt midostaurin for 3 days (6 doses), then resume midostaurin at 50 mg twice daily, and if tolerated, increase to 100 mg twice daily.
- Other grade 3/4 non-hematologic toxicities: Interrupt midostaurin until event has resolved to  $\leq$  grade 2, then resume midostaurin at 50 mg twice daily, and if tolerated, increase to 100 mg twice daily.

#### Rare But Serious Toxicities:

- Cases of interstitial lung disease and pneumonitis, some fatal, have occurred in patients treated with midostaurin as monotherapy or with chemotherapy. Monitor patients for pulmonary symptoms. Discontinue midostaurin in patients who experience signs or symptoms of interstitial lung disease or pneumonitis without an infectious etiology.

#### Specific Interventions:

- GI upset: Administer prophylactic antiemetics (eg, ondanestron or granisetron) 1 hour before treatment with midostaurin to reduce the risk of nausea and vomiting. Take doses with food.

<sup>1</sup>Please refer to package insert for full prescribing information and monitoring of hematologic or biochemical abnormalities, available at [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/207997s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf).

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



### MANAGEMENT OF AVAPRITINIB TOXICITY<sup>1</sup>

#### Limitations of use:

- Avapritinib is not recommended for the treatment of patients with advanced systemic mastocytosis (advanced SM) with platelet counts  $<50 \times 10^9/L$ .

#### Dosage and administration:

- The starting dose of avapritinib is 200 mg once daily, on an empty stomach, at least 1 hour before or 2 hours after a meal.

#### Drug interactions:

- Co-administration of avapritinib with strong and moderate CYP3A inhibitors may increase avapritinib concentrations. Avoid coadministration of avapritinib with strong and moderate CYP3A inhibitors. If coadministration of avapritinib with a moderate inhibitor cannot be avoided, reduce dose of avapritinib.
  - ▶ Avoid coadministration of avapritinib with strong and moderate CYP3A inducers.

#### Hematologic toxicities:

- Thrombocytopenia: if platelet count  $<50 \times 10^9/L$  occurs, interrupt avapritinib until platelet count is  $\geq 50 \times 10^9/L$ , then resume at a reduced dose per the package insert. If platelet counts do not recover above  $50 \times 10^9/L$ , consider platelet support. The most common hematologic laboratory abnormalities ( $\geq 30\%$ ) with any grade worsening from baseline in patients with advanced SM receiving avapritinib included decreased platelets, decreased hemoglobin, decreased neutrophils, and decreased lymphocytes.

#### Non-Hematologic toxicities:

- In patients with advanced SM who received avapritinib at 200 mg daily, intracranial hemorrhage occurred in 2 of 75 patients (2.7%) who had platelet counts  $\geq 50 \times 10^9/L$  prior to initiation of therapy and in 3 of 80 patients (3.8%) regardless of platelet counts. Monitor patients closely for the risk of intracranial hemorrhage including those with thrombocytopenia, vascular aneurysm or a history of intracranial hemorrhage or cerebrovascular accident within the prior year. Permanently discontinue avapritinib if intracranial hemorrhage of any grade occurs. Advise patients to contact their healthcare provider immediately if experiencing neurological signs and symptoms that may be associated with intracranial hemorrhage (i.e., severe headache, vomiting, drowsiness, dizziness, confusion, slurred speech, or paralysis).
- The most common adverse reactions ( $\geq 20\%$ ) at all doses were edema, diarrhea, nausea, and fatigue/asthenia.
- Cognitive effects: Grade 1: Continue avapritinib at same dose or reduced dose or withhold until improvement to baseline or resolution. Resume at same dose or reduced dose; Grade 2 or 3: Withhold avapritinib until improvement to baseline, Grade 1, or resolution. Resume at same dose or reduced dose; Grade 4: Permanently discontinue avapritinib.
- The most common non-hematologic laboratory abnormalities ( $\geq 30\%$ ) with any grade worsening from baseline in patients with advanced SM receiving avapritinib included decreased calcium, increased bilirubin, and increased aspartate aminotransferase.

<sup>1</sup>Please refer to package insert for full prescribing information and monitoring of hematologic or biochemical abnormalities, available at [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/212608s007lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212608s007lbl.pdf).

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



### NCCN Categories of Evidence and Consensus

<b>Category 1</b>	Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
<b>Category 2A</b>	Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
<b>Category 2B</b>	Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.
<b>Category 3</b>	Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise indicated.

### NCCN Categories of Preference

<b>Preferred intervention</b>	Interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability.
<b>Other recommended intervention</b>	Other interventions that may be somewhat less efficacious, more toxic, or based on less mature data; or significantly less affordable for similar outcomes.
<b>Useful in certain circumstances</b>	Other interventions that may be used for selected patient populations (defined with recommendation).

All recommendations are considered appropriate.



# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

### Discussion

This discussion corresponds to the NCCN Guidelines for Systemic Mastocytosis. Last updated: July 9<sup>th</sup>, 2021.

#### Overview .....MS-2

#### Literature Search Criteria and Guidelines Update Methodology.....MS-2

#### Diagnostic Classification .....MS-2

Cutaneous Mastocytosis .....MS-2

Systemic Mastocytosis .....MS-3

Mast Cell Activation Syndrome.....MS-3

Hereditary alpha-tryptasemia (HaT).....MS-4

#### Clinical Presentation .....MS-4

B-Findings .....MS-4

C-Findings .....MS-5

#### Diagnostic Criteria for Variants of Systemic Mastocytosis .....MS-5

Indolent Systemic Mastocytosis.....MS-5

Smoldering Systemic Mastocytosis .....MS-5

Aggressive Systemic Mastocytosis.....MS-5

Systemic Mastocytosis with an Associated Hematologic Neoplasm MS-6

Mast Cell Leukemia .....MS-6

#### Workup .....MS-6

Serum Tryptase Level .....MS-7

Bone Marrow Evaluation .....MS-7

Mast Cell Immunophenotyping ..... MS-7

Molecular Testing..... MS-8

Evaluation of B-Findings and C-Findings and Organ Involvement MS-9

24-Hour Urine Studies..... MS-10

Risk Stratification ..... MS-10

#### Treatment Considerations..... MS-12

Anti-Mediator Drug Therapy ..... MS-13

Cytoreductive Therapy ..... MS-15

Allogeneic HCT ..... MS-17

#### Response Criteria..... MS-17

#### Monitoring Response and Additional Therapy..... MS-18

ISM or SSM..... MS-18

Advanced SM..... MS-18

Additional Therapy ..... MS-18

#### Special Considerations ..... MS-19

Surgery..... MS-19

Pregnancy..... MS-19

COVID-19 Vaccination ..... MS-20

#### References..... MS-21



# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

### Overview

Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs.<sup>1</sup> In the revised 2017 WHO classification, mastocytosis was removed as one of the subtypes of myeloproliferative neoplasms (MPN) and listed as a separate major disease entity with its distinctive clinical and pathologic features.<sup>2</sup>

Mastocytosis is divided into three broad subtypes, depending on the pathology, distribution of disease, and clinical manifestations. Cutaneous mastocytosis (CM) is limited to the skin and is most commonly diagnosed in children. Systemic mastocytosis (SM) is the most common form of mastocytosis diagnosed in adults, characterized by mast cell infiltration of one or more extracutaneous organs (with or without skin involvement). Mast cell sarcoma, defined as a malignant mast cell neoplasm presenting as a solitary destructive mass, is extremely rare in humans.<sup>3</sup>

The management of patients with mastocytosis requires a multidisciplinary team approach (involving dermatologists, hematologists, pathologists, gastroenterologists, and allergists/immunologists), preferably in specialized centers with expertise in the treatment of patients with mast cell disorders.<sup>4-6</sup> The identification of *KIT* D816V mutation and the emergence of novel targeted therapies have significantly improved the diagnosis and treatment of SM.<sup>6-8</sup> However, certain aspects of clinical care, particularly the diagnosis, assessment, and management of mast cell activation symptoms, continue to present challenges.

The NCCN Guidelines provide recommendations for the diagnosis and management of patients with SM. Management of CM is not included in these guidelines. Referral to centers with expertise in mastocytosis is strongly recommended.

### Literature Search Criteria and Guidelines Update Methodology

Prior to the development of the NCCN Guidelines® for Systemic Mastocytosis, an electronic search of the PubMed database was performed to obtain key literature in SM published since the previous Guidelines update, using the following search terms: mastocytosis OR systemic mastocytosis. The PubMed database was chosen as it remains the most widely used resource for medical literature and indexes peer-reviewed biomedical literature.<sup>9</sup>

The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Clinical Trial, Phase II; Clinical Trial, Phase III; Clinical Trial, Phase IV; Guideline; Randomized Controlled Trial; Meta-Analysis; Systematic Reviews; and Validation Studies.

The data from key PubMed articles as well as articles from additional sources deemed as relevant to these guidelines as discussed by the panel during the Guidelines update have been included in this version of the Discussion section. Recommendations for which high-level evidence is lacking are based on the panel's review of lower-level evidence and expert opinion.

The complete details of the development and update of the NCCN Guidelines are available at [www.NCCN.org](http://www.NCCN.org).

### Diagnostic Classification

#### Cutaneous Mastocytosis

The diagnosis of CM requires the presence of clinical and histopathologic findings of abnormal mast cell infiltration of the dermis with no evidence of systemic mast cell infiltration either in the bone marrow or other extracutaneous organs.<sup>2</sup> CM is further subdivided into three different





# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

sub-variants: Urticaria pigmentosa (UP)/maculopapular cutaneous mastocytosis (MPCM), diffuse CM, and mastocytoma of the skin.<sup>10</sup>

### Systemic Mastocytosis

The WHO diagnostic criteria include one major diagnostic criterion (multifocal, dense infiltrates of mast cells [≥15 mast cells in aggregates] detected in the biopsy sections of bone marrow and/or other extracutaneous organs) and four minor diagnostic criteria (the presence of atypical mast cells in lesional tissues; the presence of *KIT* D816V mutation; the aberrant expression of CD25 with or without CD2 on neoplastic mast cells; and a persistently elevated serum tryptase level [>20 ng/mL]).<sup>2</sup>

The diagnosis of SM is established when one major criterion and at least one minor criterion are present, or when at least three minor criteria are present. SM is further divided into five different subvariants (based on the mast cell burden, organ involvement, and SM-related organ damage).

- Indolent SM (ISM)
- Smoldering SM (SSM)
- Aggressive SM (ASM)
- SM with an associated hematologic neoplasm (SM-AHN)
- Mast cell leukemia (MCL)

This subclassification has been validated in a number of studies.<sup>11-13</sup> The diagnostic criteria for variants of SM are outlined in [MS-5](#).

Well-differentiated SM (WDSM) is a rare variant characterized by bone marrow infiltration of round, rather than spindle-shaped mast cells often lacking *KIT* D816V mutation or that have juxtamembrane or transmembrane *KIT* mutations (exons 10-11) and low or absent CD25 expression.<sup>14</sup> WDSM is not a WHO-defined variant, but rather is a

morphologic variant that exists across the spectrum of WHO-defined subtypes of both ISM and advanced SM (ASM, SM-AHN, and MCL). WDSM has a female predominance and may have a cutaneous onset in childhood. The presence of exon 10 or 11 mutations or lack of the *KIT* D816V mutation may increase the potential for responsiveness to treatment with imatinib.<sup>15-17</sup> An increased expression of CD30 along with the absence of CD25 may be useful in the diagnosis of WDSM and aid in its distinction from other subtypes of SM.<sup>14,18</sup>

### Mast Cell Activation Syndrome

Mast cell activation syndrome (MCAS) refers to a group of disorders associated with episodic symptoms related to mast cell mediator release and can be divided into primary, secondary, and idiopathic.<sup>19-22</sup> Primary MCAS is now considered as monoclonal mast cell activation syndrome (MMAS).

MCAS is not considered a subtype of SM. MCAS is not associated with an overproliferation of cells and is not considered a prediagnostic condition that ultimately progresses to SM. Basic defining criteria of MCAS include: 1) episodic symptoms consistent with mast cell mediator release affecting greater than or equal to two organ systems; 2) a decrease in the frequency or severity, or resolution of symptoms with anti-mediator drug therapy; and 3) elevation of a validated urinary or serum marker of mast cell activation, such as serum tryptase level (which is the marker of choice).<sup>21</sup>

In patients with mast cell activation symptoms, but with normal mast cell morphology/immunophenotype without the *KIT* D816V mutation, other causes of mast cell activation should be considered (eg, secondary causes such as allergies, chronic inflammatory or neoplastic disorders, urticaria). In patients with mast cell activation symptoms for whom no



# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

cause is identified, a diagnosis of idiopathic MCAS is rendered on a provisional basis until a specific cause of mast cell activation is found.

### Hereditary alpha-tryptasemia (HαT)

More recently, some patients with mediator symptoms, including anaphylaxis, have been diagnosed with hereditary alpha-tryptasemia, a multisystem disorder characterized by duplications and triplications in the *TPSAB1* gene encoding α-tryptase. This condition is associated with elevation of the basal serum tryptase (a minimum value of 8 ng/mL, although normal, may be found in these patients) as well as symptoms including cutaneous flushing and pruritus, dysautonomia, functional gastrointestinal symptoms, chronic pain, and connective tissue abnormalities, including joint hypermobility.<sup>23</sup> HαT may be diagnosed alone, but it is also enriched in patients with SM, especially ISM or SSM. It may also be found in patients with CM. HαT is associated with an increased risk of severe mediator symptoms and anaphylaxis.<sup>24,25</sup> While it is currently unclear how this symptom complex relates to increased copy number of the *TPSAB1* gene, testing for this inherited genetic variant may be considered. Since patients with SM can have symptoms of mast cell activation and also carry a diagnosis of HαT, it is important to apply WHO criteria to formally establish the diagnosis of SM.

### Clinical Presentation

Mastocytosis is associated with a variety of symptoms related to the release of mast cell mediators.<sup>26</sup> Anaphylaxis can be a life-threatening manifestation of mast cell activation, which requires immediate medical attention, the use of epinephrine, and other supportive care measures.

While some patients present with isolated symptoms, others develop a constellation of symptoms related to mast cell activation. The most common clinical symptoms include cutaneous symptoms (eg, flushing of the face, neck, and chest; pruritus; itching, hives with or without

angioedema; skin rashes), wheezing and shortness of breath, dizziness, syncope, cardiovascular symptoms (ie, rapid heart rate, chest pain, low blood pressure), gastrointestinal symptoms (eg, diarrhea, nausea, vomiting, abdominal pain, bloating, gastroesophageal reflux disease), fatigue, musculoskeletal symptoms (ie, bone/muscle pain), and neuropsychiatric symptoms (eg, headache and/or brain fog, cognitive dysfunction, anxiety and depression).<sup>27-30</sup>

Symptoms occur either spontaneously or in response to triggers of mast cell activation (eg, sunlight, heat, cold or sudden temperature changes, physical and emotional stress, food, alcohol consumption, insect stings, venoms, infections, drugs [ie, opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics (eg, vancomycin), anesthetic agents], contrast dyes, surgery, other clinical procedures [eg, endoscopy, colonoscopy]).<sup>27,30</sup>

The mastocytosis quality-of-life questionnaire (MQLQ) and the mastocytosis symptom assessment form (MSAF) can be used for the assessment of symptoms at baseline and monitoring symptom status during the course of treatment in patients with ISM and SSM.<sup>30</sup> In the WHO diagnostic criteria, clinical signs of disease related to SM are classified as B-findings or C-findings depending on the presence or absence of organ involvement and/or organ damage.<sup>2</sup> Evaluation of B-findings and C-findings is key to establishing the diagnosis of subtype of SM.

### B-Findings

B-findings indicate a higher burden of SM and include: 1) high mast cell burden on bone marrow biopsy (>30% infiltration of cellularity by focal, dense aggregates of mast cells, AND serum tryptase level >200 ng/mL); 2) hepatomegaly without impairment of liver function, palpable splenomegaly without hypersplenism, and/or lymphadenopathy on



# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

palpation or imaging; and 3) signs of dysplasia or myeloproliferation in non-mast cell lineage(s), but criteria are not met for the definitive diagnosis of an AHN, with normal or only slightly abnormal blood counts.

### C-Findings

C-findings are defined by one or more signs of organ damage due to infiltration by neoplastic mast cells, and are common in patients with advanced SM.<sup>2</sup> Examples of organ damage include cytopenia(s) (eg, absolute neutrophil count [ANC]  $<1 \times 10^9/L$ ; hemoglobin  $<10$  g/dL; and/or platelet count  $<100 \times 10^9/L$  due to bone marrow dysfunction by neoplastic mast cell infiltration); palpable hepatomegaly with impairment of liver function, ascites, and/or portal hypertension; skeletal involvement, with large osteolyses with or without pathologic fractures; palpable splenomegaly with hypersplenism; and malabsorption (eg, hypoalbuminemia) with weight loss due of gastrointestinal mast cell infiltrates.<sup>29</sup>

## Diagnostic Criteria for Variants of Systemic Mastocytosis

### Indolent Systemic Mastocytosis

ISM is characterized by low mast cell burden, 0 or 1 B-finding, no evidence of C-findings, or an AHN.<sup>13</sup> Patients exhibit a relatively younger age at presentation, lower incidence of constitutional symptoms (15%), and a higher prevalence of skin lesions (85%) and cutaneous symptoms (78%). Patients with ISM exhibit a life expectancy similar to that of an age-matched general population, with a median survival of 301 months.<sup>13</sup> Using data from the registry of the European Competence Network on Mastocytosis (ECNM), which comprised 1639 patients with SM, Sperr et al<sup>31</sup> reported a median OS of 28.4 years (95% CI, 24.1–32.8 years) and a survival rate of 93.5% (95% CI, 90.1%–95.8%) at 10 years for patients with ISM. About 2.9% of patients will progress to advanced SM.<sup>32</sup>

Bone marrow mastocytosis (BMM) is a subvariant of ISM in which mast cell infiltration is confined to the bone marrow with no skin or multiorgan visceral lesions.<sup>13,33</sup> The incidence of symptoms associated with mast cell mediator release is higher in BMM (86% compared to 67% for ISM and 50% for SSM), but the median survival is superior for patients with BMM (not reached compared to 301 months for ISM).<sup>13</sup>

### Smoldering Systemic Mastocytosis

SSM is defined by greater than or equal to two B-findings, and no evidence of C-findings or an AHN.<sup>13</sup> SSM is characterized by a relatively high mast cell burden, older age at presentation, and higher frequency of constitutional symptoms (45%). SSM is associated with inferior median survival (120 months compared to 301 months for ISM) and a significantly higher risk of transformation to acute myeloid leukemia (AML) or ASM (18% compared to  $<1\%$  for ISM).<sup>13</sup> However, patients with SSM were significantly older; in a multivariate analysis, advanced age was the primary determinant of inferior overall survival (OS) and SSM was not independently associated with inferior OS. Owing to these clinical and prognostic differences (age distribution and risk of disease transformation), SSM was removed as a subcategory of ISM and listed as its own subvariant in the 2017 revised WHO classification.<sup>2</sup> Registry data from the ECNM revealed that the median OS was not reached and the survival rate was 84.5% (95% CI, 61.1%–84.5%) at 10 years for patients with SSM.<sup>31</sup>

### Aggressive Systemic Mastocytosis

The diagnosis of ASM requires the presence of one or more C-findings, but does not meet the criteria for MCL.<sup>2</sup> The diagnosis of ASM indicates that only morphologic evidence for mast cell disease is found; conversely, the concomitant presence of an AHN indicates a diagnosis of SM-AHN, even if C-findings are felt to be related to the mast cell component. Skin lesions are less common in ASM compared to ISM. The median survival of



# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

patients with ASM was 41 months in one study.<sup>12</sup> ASM with 5% to 19% mast cells in a bone marrow aspirate is referred to as ASM in transformation.

### Systemic Mastocytosis with an Associated Hematologic Neoplasm

SM-AHN fulfills the diagnostic criteria for SM as well as the diagnostic criteria for the AHN and is detected in about 40% of patients with SM.<sup>2</sup> C-findings may or may not be present. AHNs are of myeloid lineage in the overwhelming majority of patients (~90%) and lymphoid neoplasms (eg, chronic lymphocytic leukemia [CLL], lymphomas, multiple myeloma) are uncommon.<sup>34,35</sup> AHNs of myeloid lineage include AML, MPN, myelodysplastic syndromes (MDS), MDS/MPN (eg, chronic myelomonocytic leukemia [CMML] or MDS/MPN-unclassifiable [MPN-U]), and chronic eosinophilic leukemia, not otherwise specified (CEL, NOS).<sup>34,35</sup>

SM-AHN is characterized by older age at presentation, higher incidences of constitutional symptoms and hematologic abnormalities, and an inferior OS compared with other subtypes of SM without AHN.<sup>36</sup> The outcome of patients with SM-AHN varies with the type of AHN. Among the SM-AHN with myeloid neoplasms, one study found that SM-MDS and SM-MPN were associated with significantly longer median survival (42 months and 32 months, respectively) compared to SM-CMML (17 months), SM-MDS/MPN-U (16 months), and SM-AML (11 months).<sup>35</sup> The rate of leukemic transformation is more frequent in SM-MDS (29%) than in SM-MPN (11%) or SM-CMML (6%).<sup>34</sup>

### Mast Cell Leukemia

MCL is defined histopathologically by the presence of greater than or equal to 20% neoplastic mast cells on a bone marrow aspirate.<sup>2</sup> The aleukemic variant (<10% circulating mast cells in peripheral blood) is much more common than the leukemic variant (≥10% circulating mast

cells in peripheral blood). Acute MCL, characterized by the presence of C-findings/organ damage, is present in the majority of patients.<sup>2</sup> Chronic MCL is defined as MCL without C-findings/organ damage and may display a more indolent disease course over time, but its natural history requires more study.<sup>37-39</sup> Immunostaining with Ki-67 has been shown to differentiate between the acute and chronic variants, since most mast cells in chronic MCL stain negative for Ki-67 whereas mast cells in acute MCL frequently display Ki-67.<sup>37</sup> These findings require validation in additional studies.

MCL can present as a *de novo* disorder, or it can transform from advanced forms of SM such as ASM, SM-AHN or, very rarely, ISM.<sup>12,40,41</sup> MCL is associated with a poor prognosis regardless of the subtype or the presence of signs/symptoms of organ damage. In a study that evaluated the clinical and molecular characteristics of 28 patients with MCL, *de novo* MCL and secondary MCL resulting from leukemic transformation of SM-AHN or ASM were diagnosed in 57% and 43% of patients, respectively, with no differences in clinical, morphologic, or molecular characteristics between the two variants.<sup>41</sup> AHNs (CMML, CEL, MDS, and MDS/MPN-U) were diagnosed in 71% of MCL patients (20 out of 28) of patients and is generally associated with a worse prognosis, even within the spectrum of MCL patients. *KIT* D816V mutation was identified in 68% of patients and additional prognostically relevant mutations in *SRSF2*, *ASXL1*, or *RUNX1* (S/A/R) genes, considered high-risk mutations, were identified in 52% of patients.

### Workup

Evaluation for SM is recommended in patients with suspected clinical symptoms associated with the release of mast cell mediators or anaphylaxis, and/or increased serum tryptase level or biopsy-proven adult-onset mastocytosis in the skin (MIS).





# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

Initial evaluation should include a physical exam, skin exam for cutaneous lesions, palpation of spleen and liver, history of anaphylaxis, mast cell activation symptoms, potential triggers, and documentation of medications/transfusion history and weight loss. Laboratory evaluation should include comprehensive metabolic panel with uric acid, lactate dehydrogenase, liver function tests, CBC with differential, and serum tryptase level. Peripheral blood smear should be reviewed for the presence of mast cells and/or for the evidence of other blood cell abnormalities (eg, eosinophilia, dysplasia, monocytosis).

Additional evaluations should include a bone marrow biopsy or biopsy of organ(s) with suspected extracutaneous involvement if biopsy of that organ is felt to be important for clinical management or to ascertain whether mast cell involvement is the basis for organ damage; high-sensitivity mutation analysis for the detection of *KIT* D816V mutation and myeloid mutation panel testing; mast cell immunophenotyping by immunohistochemistry (IHC) and/or flow cytometry; imaging studies to document organomegaly, lymphadenopathy, and/or ascites (eg, B- and/or C-findings); and human leukocyte antigen (HLA) testing, if considering allogeneic hematopoietic cell transplantation (HCT) as a future option. Twenty-four-hour urine studies to document biochemical evidence of mast cell activation can be useful under selected circumstances. More details on the measurement of urinary metabolites are provided on [MS-10](#).

### Serum Tryptase Level

Serum tryptase is elevated in the vast majority of patients with SM across all subtypes.<sup>42</sup> However, a minority of patients with SM have a tryptase level below the minor diagnostic criterion level of 20 mg/mL, or more rarely in normal range, due to a very low neoplastic mast cell burden.<sup>43</sup> Elevated levels of serum tryptase have also been documented in patients with other myeloid malignancies, H<sub>2</sub>T, and renal failure.<sup>23,44,45</sup> Therefore, it is important to interpret elevated serum tryptase levels in the appropriate

context since serum tryptase may also be transiently elevated during anaphylaxis or a severe allergic reaction.<sup>46</sup>

Persistently elevated serum total tryptase (>20 ng/mL) is one of the minor criteria.<sup>2</sup> While measurement of serum tryptase level is useful to estimate mast cell burden in patients with mastocytosis, such correlations may be confounded by the presence of an AHN, and the co-occurrence of H<sub>2</sub>T, which may also contribute to elevation of the serum tryptase level.<sup>23,44,45</sup> Bone marrow evaluation should be done to confirm the diagnosis of SM in symptomatic patients with persistently elevated levels of serum tryptase.<sup>45</sup>

### Bone Marrow Evaluation

The detection of multifocal, dense infiltrates of mast cells (≥15 mast cells in aggregates) in the biopsy sections of the bone marrow and/or other extracutaneous organs is a major criterion for the diagnosis of SM. The presence of spindle-shaped or atypical mast cells in the trephine biopsy sections of bone marrow or bone marrow aspirate smears or other extracutaneous organs is one of the minor criteria.<sup>2</sup>

Bone marrow aspiration and biopsy with mast cell immunophenotyping is almost always necessary to establish the diagnosis of SM.<sup>47</sup> Bone marrow evaluation also helps in the detection of AHN, if present. Although bilateral bone marrow biopsies might be useful for the early diagnosis of SM or for the detection of minimal bone marrow involvement, a unilateral bone marrow biopsy is generally recommended.<sup>48</sup>

### Mast Cell Immunophenotyping

Immunohistochemical evaluation is necessary to confirm the diagnosis of SM in patients with low mast cell burden or if bone marrow involvement is not morphologically conspicuous on the bone marrow aspirate or core biopsy by hematoxylin and eosin (H&E) staining.<sup>49,50</sup> The expression of



# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

CD25, with or without CD2, in addition to normal mast cell markers, is a minor diagnostic criterion.<sup>2</sup>

Tryptase and CD117 are co-expressed on normal mast cells. CD117 alone is not sufficient to establish mast cell lineage. Tryptase is considered the most specific marker since this allows for the detection of small and/or immature mast cell infiltrates. However, immunostaining with neither of these markers is able to distinguish between normal and neoplastic mast cells.<sup>51-53</sup> Aberrant expression of CD2 and CD25 has been reported to be useful to differentiate mast cells in SM from normal/reactive mast cells in the bone marrow.<sup>53-55</sup> Further studies have demonstrated that CD25 is a more sensitive marker than CD2, since the latter is not expressed in mast cells of advanced SM and is only expressed in about 50% to 60% of mast cells in cases of ISM.<sup>52,56,57</sup> The use of immunostaining for CD45 in combination with CD25 has been shown to specifically identify abnormal mast cells in patients with SM, a finding that has to be confirmed in further studies.<sup>58</sup>

Cytoplasmic and/or surface expression of CD30 has also been reported in neoplastic mast cells in patients with SM.<sup>14,18,59-61</sup> Earlier reports suggested that CD30 is preferentially expressed in the neoplastic mast cells of advanced SM compared to ISM.<sup>59,60</sup> However, more recent reports confirm that CD30 is also frequently expressed in CM as well as in all subtypes of SM, suggesting that CD30 expression does not contribute to the differential diagnosis and prognostic stratification of different subtypes of SM.<sup>18,61</sup> However, an increased expression of CD30 along with the absence of CD25 may be useful in the diagnosis of WDSM and its distinction from other subtypes of SM.<sup>14,18</sup>

IHC with markers for mast cell tryptase, CD117, and CD25 should be performed for the quantification of mast cell burden in bone marrow.<sup>51-55</sup> CD30 is considered optional; it can be useful in cases where CD25 is negative.<sup>14</sup> CD34 staining may also be obtained to quantify whether the

proportion of myeloblasts is increased, especially in SM-AHN.<sup>62</sup> Flow cytometry is a complementary tool for the diagnosis or monitoring of SM. CD117, CD25, and CD2 are the standard markers; CD30 can also be considered.<sup>63,64</sup>

### Molecular Testing

*KIT* D816V mutation occurs in the majority of patients (>90%) with SM.<sup>7,34,65,66</sup> In SM-AHN, the *KIT* D816V mutation can also be found in cells comprising the AHN. However, the frequency of *KIT* D816V mutation in these cells is variable depending on subtype of AHN, being most common in patients with SM-CMML (89%), and less frequent in patients with SM-MPN (20%) and SM-AML (30%).<sup>67</sup>

In addition to *KIT* D816V mutation, prognostically relevant mutations in several other genes (*TET2*, *SRSF2*, *CBL*, *ASXL1*, *RUNX1*, *EZH2*, *JAK2*, and/or *RAS*) have also been identified in advanced SM (ASM, SM-AHN, and MCL).<sup>68-76</sup> The presence of one or more mutations beyond *KIT* D816V, particularly in the *SRSF2*, *ASXL1*, *RUNX1* (S/A/R), and/or *EZH2* genes, has been associated with significantly inferior OS and progression-free survival (PFS).<sup>70,72,73,75,76</sup> In addition, the presence of mutations in the *ASXL1*, *RUNX1*, and/or *DNMT3A* genes with variant allele frequencies (VAFs) greater than or equal to 30% has also been identified as an independent predictor for PFS in ISM.<sup>77</sup>

More refined prognostic scoring systems integrating clinical variables and high-molecular risk (HMR) mutations have been developed for the risk stratification of patients with SM (See “Risk Stratification” on [MS-10](#)).<sup>31,78,79</sup> Myeloid mutation panel (eg, containing *SRSF2*, *ASXL1*, *RUNX1*) testing should be performed on the bone marrow, but can be performed on the peripheral blood in the presence of an AHN and/or circulating mast cells.





# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

Eosinophilia is more prevalent in patients with advanced SM and is a predictor of inferior survival outcomes.<sup>80,81</sup> The *FIP1L1-PDGFR* fusion oncogene resulting from the deletion of the *CHIC2* locus at chromosome 4q12 usually presents as a chronic myeloid neoplasm with eosinophilia.<sup>82,83</sup> Atypical or spindle-shaped mast cells that also express CD25 may be found in the bone marrow of such patients, usually in a loosely scattered or interstitial pattern without forming multifocal aggregates.<sup>84</sup> While patients with the *FIP1L1-PDGFR* fusion oncogene are not considered a subtype of SM, and *KIT* D816V is rarely found in these individuals, identifying *FIP1L1-PDGFR* fusion in patients with eosinophilia is critical since it is a predictor of excellent response to imatinib.<sup>85,86</sup> The *FIP1L1-PDGFR* fusion oncogene should be tested in peripheral blood in patients with eosinophilia who do not have the *KIT* D816V mutation.

### ***KIT* D816V Mutational Analysis**

Detection of the *KIT* D816V mutation in the bone marrow, blood, or another extracutaneous organ is included as a minor criterion.<sup>2</sup> Myeloid mutation panels alone are not recommended for the detection of *KIT* D816V since such next-generation sequencing (NGS) assays can exhibit low sensitivity and higher-sensitivity assays should always be performed.

Mutation analysis for *KIT* D816V is preferably done using a bone marrow sample since the yield from the peripheral blood may be lower. Several different sensitive assays have been used for the detection of *KIT* D816V mutation, including reverse transcriptase polymerase chain reaction (RT-PCR) plus restriction fragment length polymorphism (RFLP), nested RT-PCR followed by denaturing high-performance liquid chromatography (DHPLC), peptide nucleic acid (PNA)-mediated PCR, allele-specific oligonucleotide quantitative reverse transcriptase polymerase chain reaction (ASO-qPCR)<sup>87</sup>, and digital droplet PCR.<sup>88</sup> In the absence of a highly sensitive quantitative PCR assay, qualitative PCR can be used.

ASO-qPCR is a highly sensitive method for the detection of *KIT* D816V mutation in various tissues.<sup>89</sup> Recent studies have reported the possibility of detecting the *KIT* D816V in peripheral blood using a highly sensitive ASO-qPCR or digital droplet PCR.<sup>88,90-92</sup> However, ASO-qPCR may not be useful for patients with low mast cell burden since *KIT* D816V mutation may not be detectable in the peripheral blood. In addition, ASO-qPCR also does not detect *KIT* mutations other than D816V (very rare occurring in <3% of patients). Therefore, if a diagnosis of SM is suspected, molecular testing for *KIT* D816V with a highly sensitive ASO-qPCR or digital droplet PCR assay can first be performed on peripheral blood in combination with measurement of the serum tryptase level and evaluation of clinical signs and/or symptoms suggestive of SM-related organ involvement. If positive, this should be followed by a detailed *KIT* mutation analysis on the bone marrow aspirate. *KIT* D816V mutational analysis on the bone marrow aspirate is particularly useful to establish the diagnosis of SM in patients with low mast cell burden, those with limited systemic disease who may have serum tryptase levels less than 20 ng/mL, and those who lack multifocal mast cell clusters in a bone marrow biopsy.<sup>49,50</sup>

In patients with low mast cell burden who are otherwise negative for *KIT* D816V mutation, evaluation for *KIT* D816V mutation in the skin or an extracutaneous organ besides the bone marrow could be considered.<sup>87</sup> In patients with a high mast cell burden who are otherwise negative for *KIT* D816V mutation, molecular testing should be confirmed with ASO-qPCR or digital droplet PCR, if not originally obtained with this technique. If *KIT* D816V mutation is still negative, molecular testing for *KIT* mutations other than D816V should be done, preferably using PNA-mediated PCR.<sup>93</sup> Sequencing of the whole *KIT* by NGS may be undertaken.

### **Evaluation of B-Findings and C-Findings and Organ Involvement**

B-findings and C-findings are used for the diagnosis of the WHO subtype of SM. The International Working Group-Myeloproliferative Neoplasms



# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

Research and Treatment-European Competency Network on Mastocytosis (IWG-MRT-ECNM) established eligible organ damage findings for enrollment of patients with advanced SM into clinical trials and to allow more stringent adjudication of organ damage responses to therapy. While WHO definitions of C-findings and IWG-MRT-ECNM-defined organ damage partially overlap, the latter criteria quantify the thresholds of SM-related organ damage that are eligible for response assessment on a clinical trial basis. This should permit harmonization of the types and severity of organ damage that are evaluable across studies of patients with advanced SM who are being treated with novel therapies (See *Response Criteria*).<sup>2,94</sup>

Imaging studies (CT/MRI or ultrasound of the abdomen/pelvis) are useful to document organomegaly, lymphadenopathy, and ascites in patients with advanced SM. Chest x-ray and/or CT of the thorax may be needed in selected circumstances to further assess whether pleural effusions are present in patients with advanced SM presenting with relevant pulmonary symptoms. C-findings (organ damage caused by mast cell infiltration) should be confirmed with appropriate organ-directed biopsy as needed with IHC (eg, CD117, CD25, tryptase).

Osteoporosis and osteopenia are the most common bone complications in patients with SM; the risk of osteoporosis and vertebral fractures is high in patients with ISM, and higher urinary N-methylhistamine levels are also associated with a higher risk of osteoporosis.<sup>29,95-99</sup> In advanced SM, the finding of an increased bone mineral density (BMD) compared to those without elevated BMD was associated with a more aggressive phenotype and inferior survival.<sup>99</sup>

Skeletal involvement, with large ( $\geq 2$  cm) osteolytic lesions with or without pathologic fractures is considered a C-finding. However, the presence of one or more small osteolytic and/or sclerotic lesion(s) in the absence of other C-findings is insufficient to make a diagnosis of advanced SM and

should not alone be considered an indication for cytoreductive therapy. Dual-energy x-ray absorptiometry (DEXA) scan to evaluate for osteopenia or osteoporosis and metastatic skeletal survey to evaluate for osteolytic lesions are recommended as part of the initial workup.

### 24-Hour Urine Studies

The measurement of urinary metabolites of histamine and prostaglandin in a 24-hour urine sample or spot urine has been shown to correlate with mast cell burden and activation.<sup>100</sup> N-methylhistamine, prostaglandin D2, and 2,3-dinor-11 beta-prostaglandin F2 alfa are the most commonly measured metabolites.<sup>101-106</sup> Any elevation above normal is considered significant; however, cut-off levels for significant elevation of these metabolites have not been established.

While such urine studies do not have much utility in patients with markedly elevated serum tryptase, the measurement of urinary metabolites may be useful in the diagnosis and initiation of appropriate targeted therapy for some of the mast cell activation symptoms (eg, higher urinary N-methylhistamine levels are associated with a higher risk of osteoporosis; certain symptoms associated with elevated urinary prostaglandin levels can be targeted with aspirin).<sup>97,107</sup>

### Risk Stratification

The Mayo Alliance Prognostic System (MAPS) and Mutation-Adjusted Risk Score (MARS) use a combination of clinical variables and HMR mutations for risk stratification.<sup>78,79</sup> However, since HMR mutations were not seen in patients with ISM and SSM, both MAPS and MARS are primarily applicable only for patients with advanced SM. International Prognostic Scoring System for Mastocytosis (IPSM) score is based only on the clinical variables and is useful for the risk stratification of patients with ISM/SSM and advanced SM.<sup>31</sup> The Global Prognostic Score for



# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

Mastocytosis (GPSM) is based on clinical variables that are prognostic factors for OS and PFS.<sup>108</sup>

### MAPS

In a study of 580 patients with SM (ISM/SSM, n = 291; SM-AHN, n = 199; ASM, n = 85; and MCL, n = 5), clinical variables including age greater than 60 years, advanced SM (vs. ISM/SSM), thrombocytopenia (platelets  $<150 \times 10^9/L$ ), anemia (hemoglobin level below sex-adjusted normal), and increased alkaline phosphatase (ALP) were identified as independent risk factors for survival.<sup>78</sup> In addition, the presence of *ASXL1*, *RUNX1*, and *NRAS* mutations were independently associated with inferior survival. In the combined clinical and molecular risk factor analysis, the presence of HMR mutations, advanced SM, thrombocytopenia, increased ALP, and age greater than 60 years retained prognostic significance. Patients with SM are stratified into four different risk groups (low, intermediate-1, intermediate-2, and high) with significantly different median survival (not reached, 85 months, 36 months, and 12 months, respectively). This risk stratification is applicable only for patients with advanced SM.

### MARS

In a study that included 383 patients with advanced SM (ASM, n = 30; SM-AHN, n = 181; and MCL, n = 20), age greater than 60 years, hemoglobin less than 10 g/dL, platelets less than  $100 \times 10^9$ , the presence of one HMR mutation (*SRSF2*, *ASXL1*, and/or *RUNX1* [S/A/R]), and the presence of greater than or equal to 2 S/A/R mutations were independent predictors of inferior OS.<sup>79</sup> The presence and number of S/A/R mutations had a significant prognostic impact on OS. The weighted score was developed by assigning 2 points for the presence of  $\geq 2$  S/A/R mutations and 1 point for each of the other adverse factors. Patients with advanced SM were stratified into three risk groups (low, intermediate, and high). The median OS was not reached for the low-risk group compared to 4 years and 2 years, respectively, for the intermediate and high-risk groups.

### IPSM

In a large cohort of patients with mastocytosis (n = 1639; ISM, n = 1006; SSM, n = 53; SM-AHN, n = 174 patients; ASM, n = 62; and MCL, n = 23), age greater than or equal to 60 years and ALP greater than 100 u/L were identified as predictors of higher-grade mastocytosis and OS in patients with non-advanced mastocytosis (CM, MIS, ISM, and SSM).<sup>31</sup> Age greater than or equal to 60 years, tryptase greater than or equal to 125 ng/mL, leukocytes greater than or equal to  $16 \times 10^9/L$ , hemoglobin less than or equal to 11 g/dL, platelets less than or equal to  $100 \times 10^9/L$ , and skin involvement were independent prognostic factors for OS in patients with advanced SM. IPSM was validated in a cohort of 462 patients (ISM, n = 384; SSM, n = 11; advanced SM, n = 49).

Patients with non-advanced SM were stratified into three risk groups (low, intermediate-risk 1 [INT-1], and intermediate-risk 2 [INT-2]) with significantly different OS (10-year OS rates were 87%, 52%, and 22%, respectively) and PFS (10-year PFS rates were 96%, 87%, and 76%, respectively). The difference in OS and PFS was significant among the three risk groups for patients with ISM, whereas the OS rates were not significantly between the risk groups for patients with SSM.

Patients with advanced SM were stratified into four risk groups (advanced SM 1 [AdvSM-1], advanced SM 2 [AdvSM-2], advanced SM 3 [AdvSM-3], and advanced SM 4 [AdvSM-4]). The OS for patients in risk groups AdvSM-1 and AdvSM-2 was similar to that of patients with non-advanced mastocytosis in the INT-1 and INT-2 risk groups, respectively.

### GPSM

Prognostic parameters were examined in a discovery cohort of 422 patients with SM (ISM, n = 368; SSM, n = 4; ASM, n = 18; SM-AHN, n = 31; and MCL, n = 1).<sup>108</sup> The clinical variables that were prognostic for PFS were platelet count less than or equal to  $100 \times 10^9/L$ , serum  $\beta_2$ -microglobulin greater than or equal to 2.5  $\mu g/mL$ , and serum baseline



# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

tryptase greater than or equal to 125 µg/L. The clinical variables that were prognostic for OS were hemoglobin less than or equal to 11 g/dL, serum ALP greater than or equal to 140 IU/L, and presence of *SRSF2*, *ASXL1*, *RUNX1*, or *DNMT3A* gene mutations. Using the GPSM-PFS (n = 399) and GPSM-OS (n = 411) models, patients were stratified into three risk groups (low-risk, intermediate-risk, and high-risk). The PFS at 5 years was 100%, 94%, and 47%, respectively, while the OS at 5 years was 100%, 94%, and 62%, respectively. These results were corroborated in a validation cohort of 853 patients (ISM, n = 607; SSM, n = 19; ASM, n = 44; SM-AHN, n = 171; and MCL, n = 12). After patient stratification in the low-, intermediate-, and high-risk groups using GPSM-PFS (n = 670) and GPSM-OS (n = 768) models, the 5-year PFS was 98%, 84%, and 43%, and the 5-year OS was 99%, 61%, and 30% respectively.

A comparison of different scoring models showed that the GPSM-PFS model had a high prognostic capability, especially in patients with non-advanced SM.<sup>108</sup> For patients with advanced SM, the GPSM-OS model and the IPSM model for advanced SM were the best predictive models.

### Treatment Considerations

Referral to specialized centers with expertise in the management of mastocytosis is strongly recommended.<sup>4-6</sup> Multidisciplinary collaboration with sub-specialists (eg, anesthesiologists for invasive procedures/surgery; high-risk obstetrician for pregnancy) is recommended.

Assessment of symptoms at baseline and monitoring symptom status during the course of treatment with MQLQ and MSAF is recommended for patients with ISM and SSM.<sup>30</sup> Patient-reported outcome instruments are currently under development for patients with advanced SM.

Anti-mediator drug therapy for mast cell activation symptoms (as described below) is recommended for all patients with SM. Patients should be counseled about the signs and symptoms of mast cell activation and

the importance of avoiding known triggers of mast cell activation. The signs and symptoms of mast cell activation as well the potential triggers of mast cell activation are summarized in SM-I. Anaphylactic reactions are significantly more frequent in patients with ISM and should be managed with the use of epinephrine injection. All patients should carry two auto injectors of epinephrine to manage anaphylaxis. Pre-medications are recommended for most procedures in patients with SM, since surgery, endoscopy, and other invasive and radiologic procedures can induce mast cell activation and anaphylaxis.

Cytoreductive therapy with avapritinib, midostaurin, cladribine, or peginterferon alfa-2a (discussed below) for rapid debulking of disease are options for patients with advanced SM (ASM, SM-AHN, and MCL) owing to the frequent presence of organ damage and shortened survival of this patient population. However, cladribine or peginterferon alfa-2a may also be useful in selected patients with ISM or SSM with severe, refractory symptoms related to mast cell mediator release or bone disease not responsive to anti-mediator drug therapy or bisphosphonates. Given the potential toxicities associated with cladribine therapy, including drug-related myelosuppression and infections, the risks and potential benefits of such treatment need to be weighed in this non-advanced SM population.

In patients with SM-AHN, an initial assessment is undertaken to determine whether the SM component or the AHN component requires more immediate treatment. This determination can be challenging and reflects a comprehensive evaluation of several factors, including the relative burden and/or stage of the SM and AHN disease components in the bone marrow and/or other extracutaneous organs. In some cases, organ-directed biopsy may be useful to determine whether organ damage is related to the SM or AHN or both (eg, liver biopsy in a patient with liver function abnormalities). Although chronic MCL may follow a more indolent disease course compared to acute MCL with organ damage,<sup>37-39</sup> cytoreductive therapy





# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

should still be considered for such patients given the poor prognosis of both MCL subtypes.

Enrollment in well-designed clinical trials investigating novel therapeutic strategies (eg, selective *KIT* D816 inhibitors) is encouraged to enable further advances.

### Anti-Mediator Drug Therapy

#### **Management of Chronic Symptoms Related to Mast Cell Mediator Release**

A stepwise treatment approach for specific symptoms should be considered for all patients who present with symptoms related to mast cell mediator release, as outlined in the algorithm on SM-J.<sup>109</sup> The treatment plan may vary according to specific patient scenarios. Standard doses need to be titrated. Higher doses may be necessary for symptoms refractory to standard dose treatment.

Histamine receptor type 1 (H1) and histamine receptor type 2 (H2) blockers have been shown to control skin symptoms (eg, pruritus, flushing, urticaria, angioedema dermatographism); gastrointestinal symptoms (eg, diarrhea, abdominal cramping, nausea, vomiting); neurological symptoms (eg, headache, poor concentration and memory, brain fog); cardiovascular symptoms (eg, pre-syncope, syncope, tachycardia); pulmonary symptoms (eg, wheezing, throat swelling); and naso-ocular symptoms (eg, nasal stuffiness or pruritus, conjunctival injection).<sup>110</sup>

Cromolyn sodium is effective for the management of cutaneous, gastrointestinal, and neurological symptoms.<sup>111-114</sup> In one double-blind crossover study, cromolyn sodium resulted in marked amelioration of skin pruritus, whealing, flushing, diarrhea, abdominal pain, as well as disorders of cognitive function compared to placebo.<sup>111</sup> In another double-blind crossover study, while cromolyn sodium was significantly beneficial for the treatment of gastrointestinal symptoms (diarrhea, abdominal pain, nausea, and vomiting) compared to placebo, the benefit for nongastrointestinal

symptoms was not statistically significant.<sup>112</sup> Topical cromolyn sodium (emulsion, ointment, or cream; 1%–4%) is effective for the symptomatic relief of pruritus, itch, and flare caused by intradermal histamine and can be used to decrease flare ups of cutaneous symptoms in response to triggers.<sup>113,114</sup>

Aspirin, corticosteroids, and leukotriene receptor antagonists are useful for the management of symptoms that are refractory to other treatment options.<sup>110</sup> In particular, leukotriene receptor antagonists have been used for the management of skin and gastrointestinal symptoms that have not responded to other therapies.<sup>115,116</sup> Aspirin has been shown to be effective for the management of symptoms associated with elevated urinary prostaglandin levels.<sup>117</sup> However, the risks and benefits of aspirin need to be weighed carefully since it can trigger mast cell activation in some patients.

Omalizumab, an anti-immunoglobulin E (IgE) monoclonal antibody, has been shown to be effective for symptoms related to mast cell mediator release in patients with mastocytosis.<sup>118-124</sup> In a systematic review that assessed the efficacy and safety of omalizumab for the treatment of symptoms related to mast cell mediator release in adult patients with mastocytosis, omalizumab was particularly effective for recurrent anaphylaxis, skin, and gastrointestinal symptoms as opposed to for neuropsychiatric, respiratory, and musculoskeletal symptoms.<sup>125</sup> Omalizumab can be used for the management of symptoms related to mast cell mediator release, insufficiently controlled by conventional therapy.

#### **Management of Anaphylaxis**

The prevalence of anaphylaxis has been reported in 24% to 49% of patients with SM.<sup>27,126,127</sup> Increased serum tryptase levels have been identified as a risk factor for anaphylaxis in some studies,<sup>27,128</sup> whereas other studies have identified absence of mastocytosis in skin, atopic SM,



# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

low baseline tryptase levels, and higher total IgE levels as risk factors for severe anaphylaxis.<sup>128-130</sup>

Hymenoptera venom allergy is an IgE-mediated hypersensitivity to the allergens in insect venom and accounts for 2% to 34% of all cases of anaphylaxis.<sup>131,132</sup> Hymenoptera venom allergy is an established risk factor for severe recurrent anaphylaxis in patients with SM.<sup>133</sup> Hymenoptera venom anaphylaxis is more prevalent in patients with ISM and it seems to be absent in patients with advanced SM with high mast cell burden.<sup>134</sup> Hymenoptera anaphylaxis may be the presenting symptom of mastocytosis in an otherwise healthy individual. Therefore, mastocytosis should be suspected in patients who present with anaphylactic reactions after Hymenoptera sting.

Elevated baseline serum tryptase levels and mastocytosis are considered risk factors for severe Hymenoptera venom anaphylaxis.<sup>135-138</sup> In addition, vespid venom allergy, older age, male sex, angiotensin-converting enzyme (ACE) inhibitor therapy, and previous insect stings with a less severe systemic reaction have also been identified as predictors of systemic anaphylactic reactions in patients with Hymenoptera venom allergy.<sup>137</sup> *KIT* D816V mutation has been implicated in the hyperactivity of mast cells by amplifying the IgE-dependent mast cell mediator release.<sup>139</sup> However, the exact mechanism of increased susceptibility to Hymenoptera venom anaphylaxis has not been elucidated in patients with SM.

Anaphylactic symptoms should be treated with epinephrine as first-line therapy. Antihistamines (H1 and H2 blockers) and steroids can be added as required. Systemic hives with no organ involvement can be managed with the use of antihistamines. Epinephrine injection is the preferred treatment for systemic hives with organ involvement (ie, upper/lower airway, gastrointestinal, neurological, cardiovascular) or an acute onset of anaphylaxis with the following symptoms: hypotension, laryngeal edema, vasomotor collapse, oxygen desaturation, and/or seizures.<sup>132</sup>

Venom immunotherapy (VIT) is effective for the treatment of IgE-mediated Hymenoptera venom anaphylaxis in patients with SM and has also been shown to significantly reduce the risk of anaphylaxis after a re-sting.<sup>140-143</sup> VIT is recommended for all patients with a positive skin test or a positive test for Hymenoptera-specific IgE antibodies as well as for those with a history of Hymenoptera venom anaphylaxis after an insect sting.<sup>132</sup>

Omalizumab is an effective treatment option for unprovoked anaphylaxis, Hymenoptera venom- or food-induced anaphylaxis in patients with a negative skin test, or those with a negative test for specific IgE antibodies.<sup>118-120</sup> Omalizumab can also improve tolerance while on VIT.

### **Management of Osteoporosis**

The use of bisphosphonates (with continued use of antihistamines) is recommended to resolve bone pain and improve vertebral BMD.<sup>144</sup> Pamidronate and zoledronic acid have demonstrated efficacy, resulting in significant increases in spine and hip BMD and decreases of bone turnover markers in a small series of patients with SM.<sup>145,146</sup> Peginterferon alfa may be considered for patients with refractory bone pain and/or worsening BMD on bisphosphonate therapy.<sup>147-149</sup>

Denosumab, an anti-RANKL monoclonal antibody, has also been associated with significant increases in BMD at lumbar and femoral sites, and decreases in bone turnover markers in serum (mainly C-terminal telopeptide of collagen type I and bone ALP to a lesser extent).<sup>150</sup> Denosumab can be used as an alternative treatment option for patients with bone pain not responding to bisphosphonates or for patients who are not candidates for bisphosphonates because of renal insufficiency. Vertebroplasty or kyphoplasty could also be used in selected patients for refractory pain associated with vertebral compression fractures.<sup>151</sup>





# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

### Cytoreductive Therapy

In the NCCN Guidelines, regimens for cytoreductive therapy are stratified into three categories (based on the evidence, efficacy, toxicity, pre-existing comorbidities, and in some cases access to certain agents): preferred regimens, other recommended regimens, and useful under certain circumstances.

Avapritinib<sup>152-154</sup> and midostaurin<sup>155-157</sup> are included as preferred regimens and cladribine<sup>158-160</sup> is included as an “other recommended regimen” for patients with ASM, SM-AHN, and MCL. Imatinib is included as a treatment option for patients with ASM (for *KIT* D816V mutation negative or unknown, WDSM, or if eosinophilia is present with *FIP1L1-PDGFR*A fusion gene).<sup>17,161-167</sup>

Data from clinical trials that evaluated avapritinib, midostaurin, cladribine, and imatinib in patients with SM are discussed below.

Interferon alfa (with or without prednisone) can induce a marked reduction in serum and urine metabolites of mast cell activation, reduce symptoms related to mast cell mediator release, resolve cutaneous lesions, improve skeletal disease, and improve both bone marrow mast cell burden and C-findings, across all subtypes of SM.<sup>168-171</sup> However, because of their cytostatic mechanism of action, responses may take longer to emerge, and the use of interferons may be more suitable for patients with slowly progressive disease (PD) without the need for rapid cytoreduction.

Interferon alfa-2b and peginterferon alfa-2b have been removed from the guidelines due to product discontinuation. Peginterferon alfa-2a ± prednisone is included as an “other recommended regimen” for patients with ASM and SM-AHN.

### Avapritinib

Avapritinib, a potent and selective inhibitor of *KIT* D816V, has demonstrated activity in patients with advanced SM.<sup>152-154</sup>

Data from the phase I EXPLORER trial, which consisted of 48 evaluable patients (3 patients with ASM, 35 patients with SM-AHN, and 10 patients with MCL), revealed an ORR of 77% (95% CI, 63%–88%), per modified IWG-MRT-ECNM (mIWG-MRT-ECNM) criteria.<sup>152,153</sup> A pre-specified interim analysis of the phase II PATHFINDER trial consisted of 32 evaluable patients with advanced SM: 2 patients with ASM, 26 patients with SM-AHN, and 4 patients with MCL.<sup>154</sup> Using the mIWG-MRT-ECNM response criteria, treatment with avapritinib resulted in an ORR of 75%. The ORR was lowest in patients with MCL. Patients also experienced reductions in objective measures of mast cell disease burden. The percentages of patients who achieved a 50% or greater decrease in bone marrow mast cells, *KIT* D816V variant allele fraction, and serum tryptase were 88%, 60%, and 93%, respectively. A decrease of 35% or greater in spleen volume was obtained in 66% of patients. Avapritinib was generally well tolerated. Grade 3 or 4 neutropenia, anemia, and thrombocytopenia occurred in 24%, 16%, and 16% of patients, respectively. With an incidence of 3%, the most common grade 3 or 4 non-hematologic adverse events were peripheral or periorbital edema and fatigue.

Avapritinib is FDA-approved for the treatment of adult patients with advanced SM, including ASM, SM-AHN, and MCL.

### Midostaurin

Midostaurin, an oral multikinase inhibitor, has demonstrated activity for the treatment of advanced SM (ASM, SM-AHN, and MCL).<sup>155-157</sup>

In an open-label study of 116 patients with advanced SM, 89 patients had evaluable mastocytosis-related organ damage: 16 patients with ASM, 57 patients with SM-AHN, and 16 patients with MCL. Using modified Valent



# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

and Cheson response criteria, treatment with midostaurin (100 mg twice daily) resulted in an overall response rate (ORR) of 60% (45% of the patients had a major response, defined as complete resolution of at least one type of mastocytosis-related organ damage).<sup>155</sup> Response rates were similar across all subtypes of advanced SM, *KIT* mutation status (63% for patients who were *KIT* D816V mutation-positive and 44% for those who were *KIT* D816V mutation-negative or had unknown mutation status), or exposure to previous therapy. The median OS and PFS were 29 months and 14 months, respectively. The median OS and PFS were longer for patients with ASM (not reached and 29 months, respectively) than for patients with SM-AHN (21 months and 11 months, respectively) and MCL (9 months and 11 months, respectively). In a multivariate analysis, a subtype of advanced SM other than MCL and greater than or equal to 50% reduction of bone marrow mast cell burden were identified as independent predictors of longer OS. Low-grade nausea, vomiting, and diarrhea were the most frequent adverse events. New or worsening grade 3 or 4 neutropenia, anemia, and thrombocytopenia occurred in 24%, 41%, and 29% of patients, respectively, and were more common in patients with pre-existing cytopenias.

Midostaurin is approved by the U.S. Food and Drug Administration (FDA) only for patients with a diagnosis of ASM, SM-AHN, or MCL, although it has also been shown to be effective for patients with ISM and severe symptoms related to mast cell mediator release or skin infiltration in a small phase 2 clinical trial.<sup>172</sup>

A recent study that evaluated the impact of *KIT* D816V mutation and other molecular markers on the clinical outcome of 38 patients with advanced SM treated with midostaurin found that the ORR, median duration of midostaurin treatment, and OS were significantly higher in patients with an S/A/R<sup>neg</sup> (vs. S/A/R<sup>pos</sup>) mutation profile and in patients with a greater than or equal to 25% (vs. <25%) reduction in the *KIT* D816V

allele burden using ASO-qPCR. The acquisition of additional mutations in *KRAS*, *NRAS*, *RUNX1*, *IDH2*, or *NPM1* genes was identified in patients with disease progression.<sup>173</sup>

### Cladribine

Cladribine (2-chlorodeoxyadenosine) is not approved by the FDA for SM, but is used on an off-label basis because of its activity across all subtypes of SM, including MCL refractory to prior cytoreductive therapy.<sup>158-160</sup> Cladribine may be particularly useful for patients with advanced SM when rapid debulking of disease is required.

In an analysis, 108 patients with SM treated with cytoreductive therapy, cladribine, resulted in an ORR of 56%, 50%, and 55%, respectively, in patients with ISM, ASM, and SM-AHN.<sup>159</sup> The presence of circulating immature myeloid cells was a predictor of inferior response. In a more recent study that reported the long-term safety and efficacy of cladribine in 68 patients with SM, the ORR was 72%, split between 92% for patients with ISM (major/partial 56%/36%) and 50% for those with advanced SM (major/partial 38%/13%). The median duration of response was 4 years and 3 years for ISM and ASM, respectively.<sup>160</sup> In a multivariate analysis, only mastocytosis subtypes (SM-AHN vs. ISM;  $P = .02$  and ASM vs. ISM;  $P = .006$ ) and age greater than 50 years at diagnosis were independently associated with mortality. Lymphopenia (82%), neutropenia (47%), and opportunistic infections (13%) were the most frequent grade 3 or 4 toxicities.

### Imatinib

Imatinib is very effective in the treatment of patients with eosinophilia-associated myeloid neoplasms characterized by the *FIP1L1-PDGFR* fusion tyrosine kinase.<sup>85,86</sup> It has also shown activity against the *KIT* F522C transmembrane mutation, V560G juxtamembrane mutation, germline K509I mutation, deletion of codon 419 in exon 8, and p.A502\_Y503dup mutation in exon 9.<sup>17,161-167</sup> In a study that evaluated the



# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

efficacy of imatinib in 10 patients with SM lacking the *KIT* D816V mutation and meeting criteria for WDSM (including 3 patients with ISM and 3 patients with MCL), imatinib resulted in an ORR of 50%, including early and sustained complete response (CR) in four patients and partial response (PR) in one patient with wild-type *KIT*.<sup>17</sup>

Imatinib is approved by the FDA for the treatment of adult patients with ASM without the *KIT* D816V mutation (including wild-type) or with unknown mutational status.

### Allogeneic HCT

Allogeneic HCT has been evaluated in patients with advanced SM, and the outcomes are significantly affected by the subtype of SM and the type of conditioning regimen.<sup>174-176</sup> Reduced-intensity conditioning regimens were associated with lower survival than myeloablative conditioning regimens. In the largest retrospective analysis that included 57 patients with advanced SM (median age, 46 years; SM-AHN, n = 38; MCL, n = 12; ASM, n = 7), allogeneic HCT was associated with a 70% response rate (28% CR; 21% stable disease [SD]) and the 3-year OS rate was 57% for all patients (74% for patients with SM-AHN; 43% and 17%, respectively, for patients with ASM and MCL).<sup>176</sup> MCL subtype was the strongest risk factor for poor OS.

The role of allogeneic HCT needs to be determined in a prospective trial. However, given the rarity of SM, no larger prospective trials of HCT have been initiated to confirm the role of allogeneic HCT. In 2016, a consensus opinion was published on indication for allogeneic HCT in patients with advanced SM.<sup>177</sup>

Evaluation for allogeneic HCT should be considered for patients with ASM and MCL if there is adequate response to initial treatment with cytoreductive therapy. Among patients with SM-AHN, allogeneic HCT should be considered as part of initial treatment when the AHN component

requires HCT. It should also be considered if the SM component presents as advanced SM (and there is adequate response to initial treatment with cytoreductive therapy) or progresses to advanced SM during treatment. Prophylactic anti-mediator drug therapy (corticosteroids, antihistamines, and epinephrine) should be used with the conditioning regimen in all patients.<sup>177</sup>

### Response Criteria

Response criteria for advanced SM were first published in 2003 and were subsequently modified in 2013 by the IWG-MRT and ECNM with the addition of more specific and quantifiable criteria to establish eligible organ damage findings for clinical trial enrollment and facilitate response evaluation to targeted therapies.<sup>94,178</sup> These response criteria were developed mainly for use in clinical trials. The mIWG-MRT-ECNM response criteria are currently being employed in trials of KIT inhibitors in advanced SM.<sup>179</sup> Treatment response criteria have also been published to adjudicate responses in the AHN component.

The revised 2013 IWG-MRT-ECNM response criteria delineate definitions for nonhematologic and hematologic organ damage eligible for response evaluation and adjudication of response.<sup>94</sup> ANC, transfusion-dependent and independent anemia, and thrombocytopenia are used for the assessment of hematologic organ damage. Nonhematologic organ damage is assessed based on the presence of symptomatic ascites or pleural effusion, liver function abnormalities, hypoalbuminemia, and symptomatic marked splenomegaly. The development of ascites usually reflects aggressive liver disease and may be accompanied by hepatomegaly, abnormal liver function test results, and/or portal hypertension. Hypoalbuminemia is indicative of worsening synthetic function of the liver and/or worsening nutritional status due to gastrointestinal tract infiltration by neoplastic mast cells.



# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

Clinical improvement (CI) is defined as the resolution of greater than or equal to 1 finding of nonhematologic or hematologic organ damage without concomitant worsening of other eligible organ damage.<sup>94</sup> CR and PR are defined based on the percent reduction in bone marrow mast cells and the reduction of serum tryptase levels.<sup>94</sup> In addition, the achievement of a CR or PR also requires the resolution of all or at least one CI finding, respectively. Responses (resolution of findings of organ damage as well as reduction in bone marrow mast cell burden and serum tryptase level) should be maintained or confirmed for a period of at least 12 weeks in order to fulfill the criteria for CI, CR, and PR. Additional criteria are also included for PDs, SD, and loss of response. The response criteria are summarized in the algorithm on SM-F.

## Monitoring Response and Additional Therapy

### ISM or SSM

History and physical exam, laboratory evaluation (annually for patients with ISM and every 6–12 months for patients with SSM), DEXA scan (every 1–3 years for patients with osteopenia or osteoporosis), and assessment of symptom burden and quality of life (QOL) using MSAF and MQLQ is recommended for patients with ISM and SSM.

Although increased serum beta-2-microglobulin has been identified in one study as an independent predictor of disease progression in patients with ISM, this is not routinely performed in clinical practice.<sup>11</sup> Progressively increasing serum tryptase levels have been associated with disease progression to SSM or ASM and shorter PFS in patients with ISM.<sup>180</sup> Patients with ISM and SSM should also be monitored for the development of signs of disease progression to advanced SM (eg, development of C-findings/organ damage).

### Advanced SM

Bone marrow aspirate and biopsy with cytogenetics, serum tryptase level, and additional staging studies to document organ damage are recommended for patients with ASM, SM with AHN, and MCL, if supported by increased symptoms and signs of progression (return or progression of hematologic or nonhematologic organ damage; symptomatic or progressive hepatomegaly or splenomegaly).<sup>94</sup> Repeat NGS panel testing may be considered to determine whether signs of disease progression are associated with the development of new mutations compared to baseline.

Biopsy of involved extramedullary organ may be considered to evaluate the grade and extent of SM-related organ damage.<sup>94</sup> Evaluation of organ damage in SM with an AHN might require a tissue biopsy to ascertain the relationship between organ damage and burden of mast cell infiltration and/or AHN involvement.<sup>94</sup> Additional staging studies include complete blood count for the evaluation of hematologic organ damage, liver functions tests (measurement of total bilirubin, alanine aminotransferase, aspartate aminotransferase, and serum ALP [the most common SM-associated sign of hepatic damage]) for the evaluation of nonhematologic organ damage, and imaging studies (CT or MRI) to verify physical examination findings of organ involvement or organ damage.

*KIT* D816V allele burden has been shown to correlate with serum tryptase levels and response to cytoreductive therapy. While incorporated into current clinical trials of *KIT* inhibitors, the role of *KIT* D816V allele burden monitoring during treatment has not been formally established in clinical practice.<sup>181,182</sup>

### Additional Therapy

The panel acknowledges that the 2013 IWG-MRT-ECNM response criteria were developed mainly for use in clinical trials and that clinical benefit may not reach the threshold of these response criteria.<sup>94</sup> Response





# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

assessment should be based on the improvement of symptoms related to mast cell mediator release and SM-related organ damage at the discretion of the clinician.

Continuation of prior treatment is recommended for patients achieving adequate response to anti-mediator drug therapy (ISM or SSM) or cytoreductive therapy (advanced SM). Evaluation of allogeneic HCT should be considered for patients with advanced SM (ASM, SM-AHN, or MCL) with adequate response to cytoreductive therapy and with suitable donor(s) identified.<sup>176,177</sup>

Patients with ISM or SSM with inadequate response or loss of response or progression to advanced SM should be managed with cytoreductive therapy. Patients with advanced SM with inadequate response or loss of response should be treated with alternate cytoreductive therapy not previously received. Restaging studies (as described above) are recommended prior to initiation of additional therapy. Clinical trials are always recommended for these orphan diseases, regardless of whether patients have ISM, SSM, or advanced forms of SM.

## Special Considerations

### Surgery

Mast cell activation can occur in patients with mastocytosis undergoing surgical procedures and the risk may persist for several hours after surgery due to delayed mast cell mediator release.<sup>183</sup> The primary goal is to prevent mast cell activation during and in the immediate aftermath of the surgical procedure. Multidisciplinary management is recommended with the involvement of surgical, anesthesia, and perioperative medical teams. Careful review of prior anesthetic records as well as identification and avoidance of known triggers for symptoms related to mast cell mediator release (such as temperature extremes [hypothermia or hyperthermia] and unnecessary trauma) are strongly recommended.<sup>184</sup>

The efficacy and safety of perioperative drugs in patients with SM has not been fully established, although anecdotal reports suggest that certain perioperative drugs are considered safer in patients with SM.<sup>185</sup>

Nevertheless, the use of perioperative drugs is not contraindicated in patients with SM.<sup>184,186</sup> While it is important that analgesics should not be withheld from patients with SM (since pain can be a trigger for mast cell activation), caution should be exercised with the use of opioids (eg, codeine or morphine).

Management of symptoms related to mast cell mediator release depends on their severity. The use of benzodiazepines, anti-histamines (H1 and H2 blockers), and corticosteroids is probably helpful in reducing the frequency and/or severity of symptoms related to mast cell mediator release.<sup>184,185</sup> Other options include fluid resuscitation, intravenous epinephrine, and discontinuation of the suspected drug or anesthetic agent.<sup>184</sup> The risk of anaphylaxis in the perioperative period is estimated to be higher in patients with SM relative to the general population.<sup>186</sup> In the event of anaphylaxis or other mast cell activation event, a full allergic workup should be initiated.<sup>186,187</sup> The workup should include skin tests or detection of specific IgE antibodies for the identification of IgE-mediated hypersensitivity to drugs and measurement of serum tryptase level within 30–120 minutes of onset of symptoms and also after full recovery.<sup>184,185</sup>

### Pregnancy

Although mast cells have been associated with beneficial effects in early stages of pregnancy (in terms of implantation, placentation, and fetal growth), in later stages of pregnancy, excessive release of mast cell mediators is associated with pre-term delivery.<sup>188</sup> The diagnosis of SM does not appear to have any effect on fertility. There is limited evidence regarding the impact of mastocytosis on pregnancy compared to the general population. Spontaneous miscarriages and worsening of symptoms related to mast cell activation have been reported in 20% to



# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

30% of pregnant women with mastocytosis.<sup>189-191</sup> Symptoms related to mast cell mediator release have been observed in 11% of patients without any fatal outcome.<sup>191</sup>

SM is not a contraindication to a successful pregnancy. Pregnant women with SM should be managed by a multidisciplinary team, including a high-risk obstetrician and anesthesiologist during the pre-conception, pregnancy, and peripartum period. Management of SM during pregnancy involves alleviation of symptoms related to mast cell activation with the use of acceptable medications to minimize potential harm to the fetus. Breastfeeding by patients with SM should be done in consultation with a pediatrician and International Board-Certified Lactation Consultant (IBCLC).

Avoidance of known triggers and prophylactic anti-mediator drug therapy (corticosteroids, antihistamines, and epinephrine) are standard approaches during pregnancy and the early postpartum period.<sup>192-194</sup>

Cytoreductive therapy with peginterferon alfa-2a can be considered for pregnant women with severe symptoms that are refractory to conventional therapy, although there are no sufficient data to establish the use of peginterferon alfa-2a (risk category C) in pregnancy. It should be used only if benefits outweigh potential risk to the fetus.<sup>195</sup> However, the use of cladribine, imatinib, midostaurin, and avapritinib is not recommended. Medications used to treat SM and their potential risks during both pregnancy and lactation are summarized in the algorithm on SM-K.

### COVID-19 Vaccination

Mast cell patients are a unique population with the potential for mast cell activation and/or anaphylaxis with the COVID-19 vaccines ([See the NCCN COVID-19 vaccination resource page](#)). Recommendations from the ECNM and the American Initiative in Mast Cell Diseases were recently published and some general recommendations are listed below.<sup>196</sup> Patients deemed

at high risk for vaccination include those who have previously experienced grade 1 or 2 anaphylaxis, per Brighton consensus, after the first COVID-19 shot; those with known or suspected allergy to polyethylene glycol (PEG) or polysorbate 80/20; those with prior anaphylaxis following vaccination; and those with unstable mastocytosis and severe MCAS symptoms that are not controlled. Such patients should have an adrenaline autoinjector with them and should receive the vaccine at a location with emergency awareness and that has equipment and drugs for resuscitation available. These individuals may also be evaluated by skin testing for vaccine components, such as PEG or polysorbate 80/20. Additionally, H1 antihistamine premedication should be used in these patients. Following vaccination, patients should also be supervised for 60 minutes.





### References

1. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. *Leuk Res* 2001;25:603-625. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11377686>.
2. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues (revised 4th edition). International Agency for Research on Cancer; Lyon, France; 2017.
3. Ryan RJ, Akin C, Castells M, et al. Mast cell sarcoma: a rare and potentially under-recognized diagnostic entity with specific therapeutic implications. *Mod Pathol* 2013;26:533-543. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23196796>.
4. Jawhar M, Schwaab J, Horny HP, et al. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis. *Eur J Clin Invest* 2016;46:392-397. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26914980>.
5. Sanchez-Munoz L, Morgado JM, Alvarez-Twose I, et al. Diagnosis and classification of mastocytosis in non-specialized versus reference centres: a Spanish Network on Mastocytosis (REMA) study on 122 patients. *Br J Haematol* 2016;172:56-63. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26456532>.
6. Shomali W, Gotlib J. The new tool "KIT" in advanced systemic mastocytosis. *Hematology Am Soc Hematol Educ Program* 2018;2018:127-136. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30504301>.
7. Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. *Proc Natl Acad Sci U S A* 1995;92:10560-10564. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/7479840>.
8. Reiter A, George TI, Gotlib JR. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis. *Blood* 2020;135:1365-1376. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32106312>.
9. U.S. National Library of Medicine Key MEDLINE® Indicators Available at: [http://www.nlm.nih.gov/bsd/bsd\\_key.html](http://www.nlm.nih.gov/bsd/bsd_key.html).
10. Hartmann K, Escribano L, Grattan C, et al. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. *J Allergy Clin Immunol* 2016;137:35-45. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26476479>.
11. Escribano L, Alvarez-Twose I, Sanchez-Munoz L, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. *J Allergy Clin Immunol* 2009;124:514-521. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19541349>.
12. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. *Blood* 2009;113:5727-5736. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19363219>.
13. Pardanani A, Lim KH, Lasho TL, et al. WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. *Blood* 2010;115:150-151. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20056798>.
14. Alvarez-Twose I, Jara-Acevedo M, Morgado JM, et al. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis. *J Allergy Clin Immunol* 2016;137:168-178 e161. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26100086>.
15. Alvarez-Twose I, Gonzalez P, Morgado JM, et al. Complete response after imatinib mesylate therapy in a patient with well-differentiated



# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

systemic mastocytosis. J Clin Oncol 2012;30:e126-129. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22370312>.

16. Huang L, Wang SA, Konoplev S, et al. Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: A case report. Medicine (Baltimore) 2016;95:e4934. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27741105>.

17. Alvarez-Twose I, Matito A, Morgado JM, et al. Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. Oncotarget 2017;8:68950-68963. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28978170>.

18. Morgado JM, Perbellini O, Johnson RC, et al. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis. Histopathology 2013;63:780-787. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24111625>.

19. Akin C, Scott LM, Kocabas CN, et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. Blood 2007;110:2331-2333. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17638853>.

20. Pardani A, Chen D, Abdelrahman RA, et al. Clonal mast cell disease not meeting WHO criteria for diagnosis of mastocytosis: clinicopathologic features and comparison with indolent mastocytosis. Leukemia 2013;27:2091-2094. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23896642>.

21. Akin C. Mast cell activation syndromes. J Allergy Clin Immunol 2017;140:349-355. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28780942>.

22. Valent P, Akin C, Bonadonna P, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. J Allergy Clin Immunol Pract 2019;7:1125-1133 e1121. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30737190>.

23. Lyons JJ, Yu X, Hughes JD, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet 2016;48:1564-1569. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27749843>.

24. Greiner G, Sprinzl B, Gorska A, et al. Hereditary alpha tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis. Blood 2021;137:238-247. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32777817>.

25. Lyons JJ, Chovanec J, O'Connell MP, et al. Heritable risk for severe anaphylaxis associated with increased alpha-tryptase-encoding germline copy number at TPSAB1. J Allergy Clin Immunol 2021;147:622-632. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32717252>.

26. Castells M, Austen KF. Mastocytosis: mediator-related signs and symptoms. Int Arch Allergy Immunol 2002;127:147-152. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11919427>.

27. Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008;63:226-232. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18186813>.

28. Jennings S, Russell N, Jennings B, et al. The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions. J Allergy Clin Immunol Pract 2014;2:70-76. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24565772>.

29. Gulen T, Hagglund H, Dahlen B, Nilsson G. Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease. J Intern Med 2016;279:211-228. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26347286>.

30. van Anrooij B, Kluin-Nelemans JC, Safy M, et al. Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis. Allergy 2016;71:1585-1593. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27089859>.



31. Sperr WR, Kundi M, Alvarez-Twose I, et al. International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. *Lancet Haematol* 2019;6:e638-e649. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31676322>.

32. Trizuljak J, Sperr WR, Nekvindova L, et al. Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. *Allergy* 2020;75:1923-1934. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32108361>.

33. Zanotti R, Bonadonna P, Bonifacio M, et al. Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis. *Haematologica* 2011;96:482-484. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21193416>.

34. Pardani A, Lim KH, Lasho TL, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. *Blood* 2009;114:3769-3772. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19713463>.

35. Tefferi A, Shah S, Lasho TL, et al. Practice-relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm. *Am J Hematol* 2018;93:E383-E386. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30156701>.

36. Wang SA, Hutchinson L, Tang G, et al. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chromosomal abnormalities in SM and AHNMD components. *Am J Hematol* 2013;88:219-224. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23440662>.

37. Valent P, Sotlar K, Sperr WR, et al. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. *Ann Oncol* 2014;25:1691-1700. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24675021>.

38. Valent P, Berger J, Cerny-Reiterer S, et al. Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage. *Ann Hematol*

2015;94:223-231. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25209843>.

39. Valent P, Sotlar K, Sperr WR, et al. Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features. *Leuk Res* 2015;39:1-5. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25443885>.

40. Georgin-Lavialle S, Lhermitte L, Dubreuil P, et al. Mast cell leukemia. *Blood* 2013;121:1285-1295. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23243287>.

41. Jawhar M, Schwaab J, Meggendorfer M, et al. The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. *Haematologica* 2017;102:1035-1043. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28255023>.

42. Sperr WR, Jordan JH, Fiegl M, et al. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. *Int Arch Allergy Immunol* 2002;128:136-141. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/12065914>.

43. Caughey GH. Tryptase genetics and anaphylaxis. *J Allergy Clin Immunol* 2006;117:1411-1414. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16751005>.

44. Sperr WR, El-Samahi A, Kundi M, et al. Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology. *Eur J Clin Invest* 2009;39:914-923. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19522836>.

45. Aberer E, Savic S, Brettertklieber A, et al. Disease spectrum in patients with elevated serum tryptase levels. *Australas J Dermatol* 2015;56:7-13. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24575854>.

46. Schwartz LB, Metcalfe DD, Miller JS, et al. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. *N Engl J Med* 1987;316:1622-1626. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/3295549>.



47. Horny HP, Sotlar K, Valent P. Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review. *Pathobiology* 2010;77:169-180. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20616612>.

48. Butterfield JH, Li CY. Bone marrow biopsies for the diagnosis of systemic mastocytosis: is one biopsy sufficient? *Am J Clin Pathol* 2004;121:264-267. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/14983941>.

49. Sanchez-Munoz L, Alvarez-Twose I, Garcia-Montero AC, et al. Evaluation of the WHO criteria for the classification of patients with mastocytosis. *Mod Pathol* 2011;24:1157-1168. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21552214>.

50. Reichard KK, Chen D, Pardanani A, et al. Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis. *Am J Clin Pathol* 2015;144:493-502. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26276780>.

51. Jordan JH, Walchshofer S, Jurecka W, et al. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). *Hum Pathol* 2001;32:545-552. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11381374>.

52. Horny HP, Sotlar K, Valent P. Mastocytosis: immunophenotypical features of the transformed mast cells are unique among hematopoietic cells. *Immunol Allergy Clin North Am* 2014;34:315-321. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24745676>.

53. Teodosio C, Mayado A, Sanchez-Munoz L, et al. The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis. *J Leukoc Biol* 2015;97:49-59. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25381388>.

54. Escribano L, Diaz Agustin B, Bravo P, et al. Immunophenotype of bone marrow mast cells in indolent systemic mast cell disease in adults. *Leuk Lymphoma* 1999;35:227-235. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/10706445>.

55. Sotlar K, Horny HP, Simonitsch I, et al. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. *Am J Surg Pathol* 2004;28:1319-1325. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15371947>.

56. Pardanani A, Kimlinger T, Reeder T, et al. Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients. *Leuk Res* 2004;28:777-783. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15203275>.

57. Morgado JM, Sanchez-Munoz L, Teodosio CG, et al. Immunophenotyping in systemic mastocytosis diagnosis: 'CD25 positive' alone is more informative than the 'CD25 and/or CD2' WHO criterion. *Mod Pathol* 2012;25:516-521. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22222639>.

58. Chisholm KM, Merker JD, Gotlib JR, et al. Mast cells in systemic mastocytosis have distinctly brighter CD45 expression by flow cytometry. *Am J Clin Pathol* 2015;143:527-534. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25780004>.

59. Sotlar K, Cerny-Reiterer S, Petat-Dutter K, et al. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. *Mod Pathol* 2011;24:585-595. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21186345>.

60. Valent P, Sotlar K, Horny HP. Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms. *Leuk Lymphoma* 2011;52:740-744. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21261503>.

61. Russano de Paiva Silva G, Tournier E, Sarian LO, et al. Prevalence of CD30 immunostaining in neoplastic mast cells: A retrospective immunohistochemical study. *Medicine (Baltimore)* 2018;97:e10642. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29794740>.





62. Mayado A, Teodosio C, Dasilva-Freire N, et al. Characterization of CD34(+) hematopoietic cells in systemic mastocytosis: Potential role in disease dissemination. *Allergy* 2018;73:1294-1304. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29331029>.

63. Escribano L, Garcia Montero AC, Nunez R, et al. Flow cytometric analysis of normal and neoplastic mast cells: role in diagnosis and follow-up of mast cell disease. *Immunol Allergy Clin North Am* 2006;26:535-547. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16931292>.

64. Sanchez-Munoz L, Teodosio C, Morgado JM, et al. Flow cytometry in mastocytosis: utility as a diagnostic and prognostic tool. *Immunol Allergy Clin North Am* 2014;34:297-313. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24745675>.

65. Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. *Nat Genet* 1996;12:312-314. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/8589724>.

66. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. *Blood* 2006;108:2366-2372. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16741248>.

67. Sotlar K, Colak S, Bache A, et al. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). *J Pathol* 2010;220:586-595. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20112369>.

68. Tefferi A, Levine RL, Lim KH, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFR correlates. *Leukemia* 2009;23:900-904. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19262599>.

69. Traina F, Visconte V, Jankowska AM, et al. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations

are present in systemic mastocytosis. *PLoS One* 2012;7:e43090. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22905207>.

70. Schwaab J, Schnittger S, Sotlar K, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. *Blood* 2013;122:2460-2466. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23958953>.

71. Damaj G, Joris M, Chandesris O, et al. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. *PLoS One* 2014;9:e85362. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24465546>.

72. Jawhar M, Schwaab J, Hausmann D, et al. Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. *Leukemia* 2016;30:2342-2350. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27416984>.

73. Jawhar M, Schwaab J, Schnittger S, et al. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. *Leukemia* 2016;30:136-143. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26464169>.

74. Pardanani AD, Lasho TL, Finke C, et al. ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis. *Br J Haematol* 2016;175:534-536. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26628266>.

75. Pardanani A, Lasho T, Elala Y, et al. Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival. *Am J Hematol* 2016;91:888-893. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27214377>.

76. Munoz-Gonzalez JI, Jara-Acevedo M, Alvarez-Twose I, et al. Impact of somatic and germline mutations on the outcome of systemic mastocytosis. *Blood Adv* 2018;2:2814-2828. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30373888>.



77. Munoz-Gonzalez JI, Alvarez-Twose I, Jara-Acevedo M, et al. Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis. *Blood* 2019;134:456-468. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31151985>.

78. Pardanani A, Shah S, Mannelli F, et al. Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. *Blood Adv* 2018;2:2964-2972. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30413432>.

79. Jawhar M, Schwaab J, Alvarez-Twose I, et al. MARS: Mutation-adjusted risk score for advanced systemic mastocytosis. *J Clin Oncol* 2019;37:2846-2856. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31509472>.

80. Bohm A, Fodinger M, Wimazal F, et al. Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance. *J Allergy Clin Immunol* 2007;120:192-199. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17451799>.

81. Kluin-Nelemans HC, Reiter A, Illerhaus A, et al. Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. *Leukemia* 2020;34:1090-1101. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31740811>.

82. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. *N Engl J Med* 2003;348:1201-1214. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/12660384>.

83. Cools J, Stover EH, Gilliland DG. Detection of the FIP1L1-PDGFR fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia. *Methods Mol Med* 2006;125:177-187. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16502585>.

84. Boyer DF. Blood and Bone Marrow Evaluation for Eosinophilia. *Arch Pathol Lab Med* 2016;140:1060-1067. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27684977>.

85. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFR fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. *Blood* 2003;102:3093-3096. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/12842979>.

86. Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFR fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. *Blood* 2004;104:3038-3045. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15284118>.

87. Arock M, Sotlar K, Akin C, et al. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. *Leukemia* 2015;29:1223-1232. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25650093>.

88. Greiner G, Gurbisz M, Ratzinger F, et al. Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis. *Clin Chem* 2018;64:547-555. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29237714>.

89. Kristensen T, Vestergaard H, Moller MB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. *J Mol Diagn* 2011;13:180-188. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21354053>.

90. Kristensen T, Vestergaard H, Bindslev-Jensen C, et al. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. *Am J Hematol* 2014;89:493-498. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24443360>.

91. Jara-Acevedo M, Teodosio C, Sanchez-Munoz L, et al. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications. *Mod Pathol* 2015;28:1138-1149. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26067933>.

92. Kristensen T, Vestergaard H, Bindslev-Jensen C, et al. Prospective evaluation of the diagnostic value of sensitive KIT D816V mutation





analysis of blood in adults with suspected systemic mastocytosis. *Allergy* 2017;72:1737-1743. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/28432683>.

93. Sotlar K, Escribano L, Landt O, et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. *Am J Pathol* 2003;162:737-746.

Available at: <https://www.ncbi.nlm.nih.gov/pubmed/12598308>.

94. Gotlib J, Pardanani A, Akin C, et al. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. *Blood* 2013;121:2393-2401. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/23325841>.

95. Barete S, Assous N, de Gennes C, et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. *Ann Rheum Dis* 2010;69:1838-1841. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/20570833>.

96. Rossini M, Zanotti R, Bonadonna P, et al. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. *Bone* 2011;49:880-885. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/21782049>.

97. van der Veer E, van der Goot W, de Monchy JG, et al. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. *Allergy* 2012;67:431-438. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/22229787>.

98. Degboe Y, Eischen M, Apoil PA, et al. Higher prevalence of vertebral fractures in systemic mastocytosis, but not in cutaneous mastocytosis and idiopathic mast cell activation syndrome. *Osteoporos Int* 2019;30:1235-1241. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30847528>.

99. Riffel P, Schwaab J, Lutz C, et al. An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis. *J*

*Cancer Res Clin Oncol* 2020;146:945-951. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/31980928>.

100. Metcalfe DD, Pawankar R, Ackerman SJ, et al. Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases. *World Allergy Organ J* 2016;9:7. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/26904159>.

101. Morrow JD, Guzzo C, Lazarus G, et al. Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of prostaglandin D2. *J Invest Dermatol* 1995;104:937-940. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/7769262>.

102. Oranje AP, Mulder PG, Heide R, et al. Urinary N-methylhistamine as an indicator of bone marrow involvement in mastocytosis. *Clin Exp Dermatol* 2002;27:502-506. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/12372095>.

103. Butterfield JH. Increased leukotriene E4 excretion in systemic mastocytosis. *Prostaglandins Other Lipid Mediat* 2010;92:73-76. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20380889>.

104. van Doormaal JJ, van der Veer E, van Voorst Vader PC, et al. Tryptase and histamine metabolites as diagnostic indicators of indolent systemic mastocytosis without skin lesions. *Allergy* 2012;67:683-690.

Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22435702>.

105. Divekar R, Butterfield J. Urinary 11beta-PGF2alpha and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders. *Allergy* 2015;70:1230-1238. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/26095439>.

106. Cho C, Nguyen A, Bryant KJ, et al. Prostaglandin D2 metabolites as a biomarker of in vivo mast cell activation in systemic mastocytosis and rheumatoid arthritis. *Immun Inflamm Dis* 2016;4:64-69. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/27042302>.

107. Ravi A, Butterfield J, Weiler CR. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and



# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

24-hour urine 11beta-prostaglandin2alpha. J Allergy Clin Immunol Pract 2014;2:775-778. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/25439370>.

108. Munoz-Gonzalez JI, Alvarez-Twose I, Jara-Acevedo M, et al. Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. Lancet Haematol 2021;8:e194-e204. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33508247>.

109. Castells M, Butterfield J. Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management. J Allergy Clin Immunol Pract 2019;7:1097-1106. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30961835>.

110. Cardet JC, Akin C, Lee MJ. Mastocytosis: update on pharmacotherapy and future directions. Expert Opin Pharmacother 2013;14:2033-2045. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24044484>.

111. Soter NA, Austen KF, Wasserman SI. Oral disodium cromoglycate in the treatment of systemic mastocytosis. N Engl J Med 1979;301:465-469. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/111124>.

112. Horan RF, Sheffer AL, Austen KF. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol 1990;85:852-855. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/2110198>.

113. Vieira Dos Santos R, Magerl M, Martus P, et al. Topical sodium cromoglycate relieves allergen- and histamine-induced dermal pruritus. Br J Dermatol 2010;162:674-676. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19785618>.

114. Edwards AM, Stevens MT, Church MK. The effects of topical sodium cromoglycate on itch and flare in human skin induced by intradermal histamine: a randomised double-blind vehicle controlled intra-subject design trial. BMC Res Notes 2011;4:47. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21385340>.

115. Tolar J, Tope WD, Neglia JP. Leukotriene-receptor inhibition for the treatment of systemic mastocytosis. N Engl J Med 2004;350:735-736. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/14960756>.

116. Turner PJ, Kemp AS, Rogers M, Mehr S. Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis. Pediatr Dermatol 2012;29:222-223. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22044360>.

117. Butterfield JH. Survey of aspirin administration in systemic mastocytosis. Prostaglandins Other Lipid Mediat 2009;88:122-124. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19429499>.

118. Carter MC, Robyn JA, Bressler PB, et al. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 2007;119:1550-1551. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17481708>.

119. Warrier P, Casale TB. Omalizumab in idiopathic anaphylaxis. Ann Allergy Asthma Immunol 2009;102:257-258. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19354075>.

120. Broesby-Olsen S, Vestergaard H, Mortz CG, et al. Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations. Allergy 2018;73:230-238. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28662309>.

121. Constantine GM, Bressler PB, Petroni D, et al. Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis. J Allergy Clin Immunol Pract 2019;7:1314-1316. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30149096>.

122. Lemal R, Fouquet G, Terriou L, et al. Omalizumab therapy for mast cell-mediator symptoms in patients with ISM, CM, MMAS, and MCAS. J Allergy Clin Immunol Pract 2019;7:2387-2395 e2383. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30954641>.



123. Slapnicar C, Trinkaus M, Hicks L, Vadas P. Efficacy of omalizumab in indolent systemic mastocytosis. *Case Rep Hematol* 2019;2019:3787586. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31637065>.

124. Distler M, Maul JT, Steiner UC, et al. Efficacy of omalizumab in mastocytosis: Allusive indication obtained from a prospective, double-blind, multicenter study (XOLMA Study). *Dermatology* 2020;1-11. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31958790>.

125. Jendoubi F, Gaudenzio N, Gallini A, et al. Omalizumab in the treatment of adult patients with mastocytosis: A systematic review. *Clin Exp Allergy* 2020;(Epub Ahead of Print). Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32107810>.

126. Gonzalez de Olano D, de la Hoz Caballer B, Nunez Lopez R, et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). *Clin Exp Allergy* 2007;37:1547-1555. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17883734>.

127. Gulen T, Hagglund H, Dahlen B, Nilsson G. High prevalence of anaphylaxis in patients with systemic mastocytosis - a single-centre experience. *Clin Exp Allergy* 2014;44:121-129. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24164252>.

128. Gorska A, Niedoszytko M, Lange M, et al. Risk factors for anaphylaxis in patients with mastocytosis. *Pol Arch Med Wewn* 2015;125:46-53. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25578100>.

129. Alvarez-Twose I, Zanotti R, Gonzalez-de-Olano D, et al. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. *J Allergy Clin Immunol* 2014;133:520-528. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23921094>.

130. Gulen T, Ljung C, Nilsson G, Akin C. Risk factor analysis of anaphylactic reactions in patients with systemic mastocytosis. *J Allergy*

*Clin Immunol Pract* 2017;5:1248-1255. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28351784>.

131. Niedoszytko M, Bonadonna P, Oude Elberink JN, Golden DB. Epidemiology, diagnosis, and treatment of Hymenoptera venom allergy in mastocytosis patients. *Immunol Allergy Clin North Am* 2014;34:365-381. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24745680>.

132. Jimenez-Rodriguez TW, Garcia-Neuer M, Alenazy LA, Castells M. Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers. *J Asthma Allergy* 2018;11:121-142. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29950872>.

133. Valent P. Risk factors and management of severe life-threatening anaphylaxis in patients with clonal mast cell disorders. *Clin Exp Allergy* 2014;44:914-920. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24702655>.

134. van Anrooij B, van der Veer E, de Monchy JG, et al. Higher mast cell load decreases the risk of Hymenoptera venom-induced anaphylaxis in patients with mastocytosis. *J Allergy Clin Immunol* 2013;132:125-130. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23498593>.

135. Haeberli G, Bronnimann M, Hunziker T, Muller U. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. *Clin Exp Allergy* 2003;33:1216-1220. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/12956741>.

136. Bonadonna P, Perbellini O, Passalacqua G, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. *J Allergy Clin Immunol* 2009;123:680-686. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19135713>.

137. Rueff F, Przybilla B, Bilo MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom



Hypersensitivity. J Allergy Clin Immunol 2009;124:1047-1054. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19895993>.

138. Alvarez-Twose I, Bonadonna P, Matito A, et al. Systemic mastocytosis as a risk factor for severe Hymenoptera sting-induced anaphylaxis. J Allergy Clin Immunol 2013;131:614-615. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23273956>.

139. Castells MC, Hornick JL, Akin C. Anaphylaxis after hymenoptera sting: is it venom allergy, a clonal disorder, or both? J Allergy Clin Immunol Pract 2015;3:350-355. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25858055>.

140. Gonzalez de Olano D, Alvarez-Twose I, Esteban-Lopez MI, et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 2008;121:519-526. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18177694>.

141. Bonadonna P, Gonzalez-de-Olano D, Zanotti R, et al. Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations. J Allergy Clin Immunol Pract 2013;1:474-478. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24565619>.

142. Verburg M, Oldhoff JM, Klemans RJ, et al. Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis. Eur Ann Allergy Clin Immunol 2015;47:192-196. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26549336>.

143. Rueff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001;108:1027-1032. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11742283>.

144. Rossini M, Zanotti R, Orsolini G, et al. Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis. Osteoporos Int 2016;27:2411-2421. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26892042>.

145. Marshall A, Kavanagh RT, Crisp AJ. The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. Br J Rheumatol 1997;36:393-396. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/9133977>.

146. Rossini M, Zanotti R, Viapiana O, et al. Zoledronic acid in osteoporosis secondary to mastocytosis. Am J Med 2014;127:1127 e1121-1124. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24954632>.

147. Lehmann T, Beyeler C, Lammle B, et al. Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B. Br J Rheumatol 1996;35:898-900. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/8810675>.

148. Weide R, Ehlenz K, Lorenz W, et al. Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Ann Hematol 1996;72:41-43. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/8605279>.

149. Laroche M, Livideanu C, Paul C, Cantagrel A. Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis. Am J Med 2011;124:776-778. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21787907>.

150. Orsolini G, Gavioli I, Tripi G, et al. Denosumab for the treatment of mastocytosis-related osteoporosis: a case series. Calcif Tissue Int 2017;100:595-598. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28229176>.

151. Kruger A, Hamann C, Brendel C, et al. Multimodal therapy for vertebral involvement of systemic mastocytosis. Spine (Phila Pa 1976) 2009;34:E626-628. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19644322>.

152. Gotlib J, Radia DH, George TI, et al. Avapritinib induces responses in patients (pts) with advanced systemic mastocytosis (AdvSM), regardless of prior midostaurin therapy [abstract]. EHA Congress 2020:Abstract EP1079. Available at:





153. Gotlib J, Radia DH, George TI, et al. Pure pathologic response is associated with improved overall survival in patients with advanced systemic mastocytosis receiving avapritinib in the phase I EXPLORER study [abstract]. *Blood* 2020;136:37-38. Available at: <https://doi.org/10.1182/blood-2020-137413>.

154. Deangelo DJ, Reiter A, Radia D, et al. PATHFINDER: Interim analysis of avapritinib in patients with advanced systemic mastocytosis (AdvSM) [abstract]. AACR Annual Meeting 2021:Abstract CT023. Available at:

155. Gotlib J, Kluin-Nelemans HC, George TI, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. *N Engl J Med* 2016;374:2530-2541. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27355533>.

156. Chandesris MO, Damaj G, Canioni D, et al. Midostaurin in advanced systemic mastocytosis. *N Engl J Med* 2016;374:2605-2607. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27355555>.

157. DeAngelo DJ, George TI, Linder A, et al. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. *Leukemia* 2018;32:470-478. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28744009>.

158. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. *Blood* 2003;102:4270-4276. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/12933573>.

159. Lim KH, Pardanani A, Butterfield JH, et al. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. *Am J Hematol* 2009;84:790-794. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19890907>.

160. Barete S, Lortholary O, Damaj G, et al. Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. *Blood* 2015;126:1009-1016; . Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26002962>.

161. Frost MJ, Ferrao PT, Hughes TP, Ashman LK. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. *Mol Cancer Ther* 2002;1:1115-1124. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/12481435>.

162. Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. *Exp Hematol* 2003;31:686-692. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/12901973>.

163. Akin C, Fumo G, Yavuz AS, et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. *Blood* 2004;103:3222-3225. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15070706>.

164. Zhang LY, Smith ML, Schultheis B, et al. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. *Leuk Res* 2006;30:373-378. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16183119>.

165. Heinrich MC, Joensuu H, Demetri GD, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. *Clin Cancer Res* 2008;14:2717-2725. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18451237>.

166. Vega-Ruiz A, Cortes JE, Sever M, et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. *Leuk Res* 2009;33:1481-1484. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19193436>.

167. Mital A, Piskorz A, Lewandowski K, et al. A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib. *Eur J Haematol* 2011;86:531-535. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21362052>.

168. Delaporte E, Pierard E, Wolthers BG, et al. Interferon-alpha in combination with corticosteroids improves systemic mast cell disease. *Br J*



# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

Dermatol 1995;132:479-482. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/7718472>.

169. Casassus P, Caillat-Vigneron N, Martin A, et al. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. *Br J Haematol* 2002;119:1090-1097. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/12472593>.

170. Hauswirth AW, Simonitsch-Klupp I, Uffmann M, et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. *Leuk Res* 2004;28:249-257. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/14687620>.

171. Simon J, Lortholary O, Caillat-Vigneron N, et al. Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature. *Pathol Biol (Paris)* 2004;52:294-299. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/15217717>.

172. van Anrooij B, Oude Elberink JNG, Span LFR, et al. Midostaurin in patients with indolent systemic mastocytosis: An open-label phase 2 trial. *J Allergy Clin Immunol* 2018;142:1006-1008 e1007. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/29890238>.

173. Jawhar M, Schwaab J, Naumann N, et al. Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. *Blood* 2017;130:137-145. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/28424161>.

174. Przepiorka D, Giral S, Khouri I, et al. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. *Am J Hematol* 1998;57:24-28. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/9423812>.

175. Nakamura R, Chakrabarti S, Akin C, et al. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. *Bone Marrow Transplant* 2006;37:353-358. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16400343>.

176. Ustun C, Reiter A, Scott BL, et al. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. *J Clin Oncol* 2014;32:3264-3274. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/25154823>.

177. Ustun C, Gotlib J, Popat U, et al. Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis. *Biol Blood Marrow Transplant* 2016;22:1348-1356. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/27131865>.

178. Valent P, Akin C, Sperr WR, et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. *Leuk Res* 2003;27:635-641. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/12681363>.

179. Shomali W, Gotlib J. Response criteria in advanced systemic mastocytosis: Evolution in the era of KIT inhibitors. *Int J Mol Sci* 2021;22. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33804174>.

180. Matito A, Morgado JM, Alvarez-Twose I, et al. Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome. *PLoS One* 2013;8:e76116. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/24155887>.

181. Erben P, Schwaab J, Metzgeroth G, et al. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. *Ann Hematol* 2014;93:81-88. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/24281161>.

182. Hoermann G, Gleixner KV, Dinu GE, et al. The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease. *Allergy* 2014;69:810-813. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/24750133>.

183. Pardanani A. How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). *Blood* 2013;121:3085-3094. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/23426950>.





# NCCN Guidelines Version 3.2021

## Systemic Mastocytosis

184. Dewachter P, Castells MC, Hepner DL, Mouton-Faivre C. Perioperative management of patients with mastocytosis. *Anesthesiology* 2014;120:753-759. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24135579>.

185. Hermans MAW, Arends NJT, Gerth van Wijk R, et al. Management around invasive procedures in mastocytosis: An update. *Ann Allergy Asthma Immunol* 2017;119:304-309. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28866309>.

186. Matito A, Morgado JM, Sanchez-Lopez P, et al. Management of anesthesia in adult and pediatric mastocytosis: a study of the spanish network on mastocytosis (REMA) based on 726 anesthetic procedures. *Int Arch Allergy Immunol* 2015;167:47-56. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26160029>.

187. Guyer AC, Saff RR, Conroy M, et al. Comprehensive allergy evaluation is useful in the subsequent care of patients with drug hypersensitivity reactions during anesthesia. *J Allergy Clin Immunol Pract* 2015;3:94-100. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25577625>.

188. Woidacki K, Zenclussen AC, Siebenhaar F. Mast cell-mediated and associated disorders in pregnancy: a risky game with an uncertain outcome? *Front Immunol* 2014;5:231. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24904581>.

189. Worobec AS, Akin C, Scott LM, Metcalfe DD. Mastocytosis complicating pregnancy. *Obstet Gynecol* 2000;95:391-395. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/10711550>.

190. Ciach K, Niedozytko M, Abacjew-Chmylko A, et al. Pregnancy and delivery in patients with mastocytosis treated at the Polish Center of the European Competence Network on Mastocytosis (ECNM). *PLoS One* 2016;11:e0146924. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26796887>.

191. Matito A, Alvarez-Twose I, Morgado JM, et al. Clinical impact of pregnancy in mastocytosis: a study of the Spanish Network on

Mastocytosis (REMA) in 45 cases. *Int Arch Allergy Immunol* 2011;156:104-111. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21447966>.

192. Kar S, Krishnan A, Preetha K, Mohankar A. A review of antihistamines used during pregnancy. *J Pharmacol Pharmacother* 2012;3:105-108. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22629082>.

193. Ulbrich F, Engelstadter H, Wittau N, Steinmann D. Anaesthetic management of emergency caesarean section in a parturient with systemic mastocytosis. *Int J Obstet Anesth* 2013;22:243-246. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23707036>.

194. Lei D, Akin C, Kovalszki A. Management of mastocytosis in pregnancy: a review. *J Allergy Clin Immunol Pract* 2017;5:1217-1223. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28739366>.

195. Beauverd Y, Radia D, Cargo C, et al. Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series. *Haematologica* 2016;101:e182-184. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26819057>.

196. Bonadonna P, Brockow K, Niedozytko M, et al. COVID-19 vaccination in mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). *J Allergy Clin Immunol Pract* 2021. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33831618>.